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                                                                                                                     To my family
  
ABSTRACT 
The treatment goal in type 1 diabetes is to achieve near-normal glycemia. Despite of the 
advancements of subcutaneous insulin therapy and glucose monitoring, metabolic control is 
not fully normalized and secondary endocrine disturbances in the growth-hormone (GH) - 
Insulin-like Growth Factor (IGF)-axis are important for the deterioration of metabolic 
control, particularly in children at puberty. The long-acting insulin analogs, glargine and 
detemir, have prolonged effect duration compared to intermediate-acting NPH insulin. 
Sustained nightly insulin actions could be particularly important in pubertal children with 
type 1 diabetes by opposing the low IGF-I production and increase feedback inhibition of 
elevated GH. Even the successive decline in endogenous insulin production could be 
affected. The purpose of this thesis was to evaluate if glargine or detemir, compared to NPH, 
could improve metabolic control, prolong endogenous insulin production and reverse the 
abnormalities in the GH-IGF-axis in children and adolescents with type 1 diabetes. 
In Paper I we studied the effects of changing insulin therapy from NPH to glargine for up to 
12 weeks on the GH-IGF-axis and metabolic control in 12 pubertal subjects with type 1 
diabetes. A fifty percent increase in IGF-I levels, decreased overnight IGFBP-1 secretion and 
unchanged overnight GH secretion were associated with a 1 % unit (10 mmol/mol) lower (P= 
0.008) 12-week HbA1c. These findings indicate that glargine reverses some of the 
abnormalities in the GH-IGF-axis and improves metabolic control. Suppression of IGFBP-1 
suggests that hepatic insulin sensitivity is improved. 
In Paper II we retrospectively compared the first 49 children and adolescents that we treated 
with glargine from diagnosis of type 1 diabetes with 49 patients treated with NPH, for up to 
one year. We found 0.8 % unit (8 mmol/mol) lower (P < 0.01) 12-month HbA1c and lower 
insulin requirements in the glargine treated subjects without affecting weight gain. These 
findings support a long-term improvement of HbA1c in children and adolescents treated from 
diagnosis with glargine. We hypothesized that improved metabolic control and lower insulin 
requirements could result from normalization of the GH-IGF-axis and/or improved 
endogenous insulin production. 
In Paper III we randomized children and adolescents stratified for puberty to treatment with 
glargine or detemir vs. NPH from diagnosis of type 1 diabetes. We found 9 mmol/mol (0.9 % 
unit) lower (P = 0.008) 12-month HbA1c and lower fasting-glucose with glargine or detemir 
in pubertal children, with no difference in prepubertal children. Meal-stimulated C-peptide 
AUC or glucose variability by CGM did not differ. These findings demonstrate that long-
term improvement of metabolic control is obtained with glargine or detemir treatment but not 
associated with improved preservation of beta cell function. 
In Paper IV we reported changes in the GH-IGF-axis in the subjects studied in paper III. We 
found lower 12-month IGFBP-1 with glargine or detemir in pubertal subjects. IGF-I SDS was 
subnormal from diagnosis throughout the 12 months study, particularly low in the pubertal 
individuals, and did not differ among the treatment groups. Lower IGFBP-1 suggests that 
hepatic insulin action is improved, which may have contributed to the improved 12-month 
HbA1c. However, the improved hepatic insulin action with long-acting insulin analogs was 
not sufficient to normalize IGF-I. 
In summary, this thesis supports that long-acting insulin analogs, glargine or detemir, are 
used from diagnosis of type 1 diabetes in pubertal children with insulin injection therapy to 
improve metabolic control. Although endogenous insulin secretion is not better preserved and 
IGF-I remains subnormal, hepatic insulin sensitivity may be improved as indicated by lower 
IGFBP-1. Given the link between abnormalities in the GH-IGF-axis associated with 
subcutaneous insulin therapy and the development of diabetic complications new treatment 
strategies are needed until beta-cell function can be fully preserved. 
SAMMANFATTNING PÅ SVENSKA 
Typ 1 diabetes orsakas av autoimmun nedbrytning av de insulinproducerande cellerna i 
bukspottkörteln. De nordiska länderna har högst förekomst i världen av typ 1 diabetes hos 
barn och ungdomar. Målet med insulin-injektionsbehandlingen är att hålla blodsockret på en 
så normal nivå som möjligt, vilket kan följas genom kontroll av långtidsblodsockret, HbA1c. 
Förutom snabbverkande insulin vid måltider ges ett basinsulin med längre verkan. De senaste 
femton åren har två basinsuliner, glargine och detemir, s.k. analoger med längre verkan, tagits 
fram som alternativ till medellångverkande NPH insulin. Innan detta avhandlingsarbete 
påbörjades saknades studier av barn och ungdomar som klart visade att långverkande insulin 
analoger gav bättre HbA1c över ett år. Bättre insulinverkan på natten kan vara extra viktig 
under puberteten, för att höja nivåerna av hormon med insulin-liknande effekt (Insulin-like 
Growth Factor I; IGF-I) och motverka en kompensatorisk höjning av hormon med insulin-
motverkande effekt (tillväxthormon; GH). I denna avhandling har vi undersökt om 
långverkande basinsulin har fördelar framför basinsulin med medellång verkan, vad gäller 
HbA1c, kroppens egen insulin produktion, som finns kvar under några år från diabetes 
insjuknandet och nivåerna av GH-IGF-axelns hormoner. 
I studie I undersökte vi effekterna på GH-IGF-axeln och HbA1c efter byte av basinsulin-
behandling från NPH till glargine under 12 veckor hos 12 pubertala ungdomar med typ 1 
diabetes. Vi fann ett väsentligt lägre HbA1c, markant ökning av IGF-I, sänkt nattligt IGFBP-1 
samt oförändrad nattlig nivå av GH. Dessa fynd talar för att glargine delvis kan återställa 
störningar i GH-IGF-axeln samt förbättra långtidsblodsockret. 
I studie II samlade vi in data från 49 barn och ungdomar, som vi behandlade från diagnos av 
typ 1 diabetes med glargine, efter att det blivit tillgängligt, och jämförde med 49 barn och 
ungdomar, som tidigare behandlats med NPH med samma omhändertagande. Vi visade att 
glargine-behandlade patienter hade väsentligt bättre HbA1c och samtidigt lägre insulindos 
efter 12 månader. Detta talar för att behandling med glargine från diabetesdebut ger bättre 
långtidsblodsocker. De första två studierna var grunden för vår hypotes att en återställning av 
GH-IGF-axeln och/eller förbättrad kroppsegen insulinproduktion är viktig för det förbättrade 
långtidsblodsockret. 
Studie III var en randomiserad kontrollerad studie där vi jämförde basinsulinbehandling med 
glargine eller detemir med NPH till barn och ungdomar från diagnos av typ 1 diabetes. Vi 
visade en sänkning av 12-månaders HbA1c och ett lägre faste-blodsocker hos pubertala 
ungdomar behandlade med glargine eller detemir, men ingen skillnad hos prepubertala barn. 
Det fanns ingen skillnad i kroppsegen insulinproduktion eller blodsockervariabilitet.  
I studie IV undersökte vi förändringar i GH-IGF-axeln hos de ungdomar som studerats i 
studie III. Vi fann lägre 12-månaders IGFBP-1 med glargine eller detemir. IGF-I var 
subnormalt för åldern under hela studiens första år och det var inga skillnader mellan 
behandlingsgrupperna. Lägre IGFBP-1 talar för att bättre insulinkänslighet på levernivå kan 
ha bidragit till att förbättra HbA1c. 
Sammanfattningsvis talar denna avhandling för att behandling med långverkande 
basinsuliner, glargine och detemir, bör användas från diagnos av typ 1 diabetes hos ungdomar 
i pubertet, för att förbättra den metabola kontrollen. Den kroppsegna insulinproduktionen 
förbättras inte genom denna behandling men en viss återställning av GH-IGF-axeln sker, 
talande för att insulinkänsligheten på levernivå är förbättrad. I avvaktan på en behandling, 
som återställer den egna insulinproduktionen, skulle det behövas en behandling som 
normaliserar GH-IGF-axeln och minskar risken för komplikationer. 
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THESIS AT A GLANCE 
 Paper AIM METHOD/DESIGN RESULTS CONCLUSIONS 
I To study effects of 
changing from 
NPH to glargine on 
the GH-IGF-axis 
and its association 
with metabolic 
control in 
adolescents with 
type 1 diabetes. 
12 pubertal subjects with type 
1 diabetes were studied with 
blood sampling every 30 min 
for 20 hours, CGM and 
microdialysis once on NPH 
and once 6 weeks after starting 
glargine. Fasting samples for 
IGF-I and HbA1c were 
obtained at 1, 2, 4, 8 and 12 
weeks. 
HbA1c decreased from 
8.3±0.6 to 7.3±0.3%, 
(P<0.01) at 12 weeks.  
IGF-I increased by 50 % and 
the change was inversely 
correlated with HbA1c. 
IGFBP-1 decreased while 
GH was unchanged.  
Treatment with glargine 
normalizes IGF-I. The 
increase in IGF-I correlates 
with decreased HbA1c.The 
decrease in IGFBP-1, 
suggests that hepatic insulin 
action is improved and the 
increase in IGF-I indicate 
that GH receptor function is 
normalized.  
II To compare 
metabolic control 
during the first year 
in children with 
type 1 diabetes 
treated from 
diagnosis with 
glargine vs. NPH. 
Retrospective descriptive 
study of the 49 first patients 
treated with glargine from 
diagnosis, compared with 49 
consecutive children treated 
with NPH. HbA1c, reported 
insulin requirements and 
change in weight were studied 
at 3, 6, and 12 months diabetes 
duration. 
12-month HbA1c was lower 
with glargine vs. NPH (6.3% 
vs. 7.1%, P<0.01). 12-month 
insulin dose was lower with 
glargine (0.6 IU / kg vs. 0.85 
IU / kg, P<0.001). 
Glargine treatment from 
diagnosis improves long-
term metabolic control. We 
hypothesized that improved 
metabolic control and lower 
insulin requirements could 
result from normalization of 
the GH-IGF-axis and/or 
improved endogenous 
insulin production.  
III To study if 
treatment with 
long-acting insulin 
analogs, glargine or 
detemir, in children 
and adolescents 
from diagnosis of 
type 1 diabetes 
results in better 12-
month metabolic 
control and if this 
could at least partly 
be explained by 
preserved 
endogenous insulin 
production. 
Prospective 12-month study of 
120 children and adolescents, 
stratified for puberty and 
randomized at diagnosis to 
NPH, glargine or detemir 
(1:1:1) in an MIT regimen 
with insulin aspart. Patients 
were studied at diagnosis and 
at 2 weeks, 3, 6, 9 and 12 
months with anthropometric 
data, bioimpedance, blood 
samples for HbA1c and 
fasting-glucose. 3 days CGM 
for study of glucose variability 
at 3 occasions. Endogenous 
insulin production was 
determined by MMTT (mixed 
meal tolerance test) at 4 
different time-points (2 weeks, 
3, 6 and 12 months). 
The 12-month HbA1c was 
lower in children treated 
with analogs vs. NPH (52.7 
±1.0 vs. 57.9±2.2 mmol/mol, 
P=0.019). The difference 
was due to lower HbA1c in 
children in puberty at 
inclusion (60.2±3.2 vs. 
51.0±1.7 mmol/mol, P= 
0.008). At 12 months, f- 
glucose was lower in 
pubertal children on analogs 
vs. NPH (P=0.017).Glucose 
variability assessed by CGM 
and endogenous insulin 
production measured as 
stimulated C-peptide did not 
differ. No differences were 
found between glargine and 
detemir except for higher 
insulin dose with detemir.  
This is the first randomized 
controlled trial from 
diagnosis of type 1 diabetes 
in children and adolescents 
to demonstrate lower HbA1c 
and lower fasting-glucose 
with glargine or detemir, 
compared to NPH in 
pubertal children. These 
findings could not be 
explained by improved 
preservation of beta cell 
function. 
 
IV To study if 
treatment with 
long-acting insulin 
analogs from the 
onset of type 1 
diabetes in 
adolescents results 
in changes in the 
GH-IGF-axis incl. 
increased IGF-I and 
decreased IGFBP-1 
In the same study settings as in 
paper III. Blood samples for 
IGF-I and IGFBP-1 were taken 
before iv.insulin, before 
randomization to glargine, 
detemir or NPH and at 2 
weeks and 3, 6, and 12 
months. 
The 12-month IGFBP-1 was 
lower in pubertal children 
treated with analogs, 
glargine or detemir vs. NPH 
(69.4±6.9 vs. 98.7±13.9 µg/l, 
P= 0.04). IGF-I SDS was 
subnormal from diagnosis 
throughout the 12 months, 
particularly low in the 
pubertal individuals, and did 
not differ among the 
treatment groups. 
Lower IGFBP-1 suggests 
that hepatic insulin action 
was improved which may 
contribute to the improved 
12-month HbA1c in children 
with type 1 diabetes treated 
with glargine or detemir. 
However, the improved 
hepatic insulin action with 
long-acting insulin analogs 
was not sufficient to increase 
IGF-I.   
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1 INTRODUCTION 
In my clinical work I meet children with type 1 diabetes and their families almost every 
day. I see that they struggle to find a way to cope with the disease and that their daily lives 
are deeply affected. They live always with the fear of acute and long-term complications. 
Most of all they have to follow the child’s blood sugar levels and repeatedly adjust the 
insulin dose. It has been said that they must act like a beta-cell, taking blood sugar levels 
into consideration as often as possible, and use this information to make decisions about 
insulin dosing. Many of my patients are teenagers who, in addition to all the other issues 
related to adolescence also struggle with a disease that, owing to hormonal changes, 
becomes even harder to manage during these years. In order to confront these challenges in 
a fruitful way, both children and adolescents need all the help they can get from various 
sources. For one thing, they need insulin therapy with an action profile that mimics the 
physiological release of insulin.  
 
When I started working in the area of diabetes, insulin analogs, with a target to be short 
acting and to accompany a meal, had been in use for some years and they were very useful 
and appreciated by both children and parents. However, no basal insulin could meet the 
standard of physiological insulinization, especially the increased need for insulin at dawn 
during puberty (Dunger 1992). In 2002 we started using the long-acting basal insulin 
analog, glargine, which has a 24 hours action profile (Wang, Carabino et al. 2003). After 
some months of glargine usage clinical opinion indicated that this treatment was much 
appreciated and produced a better glucose profile than older treatments. Our research group 
then decided to investigate whether the clinical observations of improved insulinization 
could be replicated in research studies. For me, a very clinically oriented medical doctor, 
with a heart for the patients, this was an ideal entrée into research. 
 
Type 1 diabetes most often emerges early in life and as a chronic disease it cannot be 
forgotten for a single day. Its development is influenced by both genetic and environmental 
factors. Incidence is high in Sweden and has almost doubled during the last decades. There 
are several theories regarding this increase. The goal in treating type 1 diabetes is to 
maintain blood glucose levels that are as normal as possible. Long-term deteriorated 
metabolic control leads to both micro- and macro-vascular complications. It has become 
well known since the large Diabetes Control and Complications Trial (DCCT ) was 
conducted that it is possible to delay these complications with better blood sugar control 
achieved through intensive insulin treatment (DCCT 1993). 
 
To achieve good metabolic control, insulin treatment must mimic the physiological release 
of insulin. Insulin regimens that employ the intermediate-acting, Neutral Protamin 
Hagedorn insulin (NPH) fail to do this (Lepore, Pampanelli et al. 2000), so instead multiple 
injection therapy (MIT) with long-acting analogs, glargine or detemir, (Heise and Pieber 
2007) or insulin pump treatment (CSII) is preferred (Bolli, Andreoli et al. 2011). The 
Growth Hormone (GH) Insulin-like Growth Factor (IGF)-axis acts near related to insulin in 
controlling both growth and metabolism. During puberty GH levels increase, leading to 
insulin resistance and in teenagers with type 1 diabetes a deteriorated metabolic control. 
Treating adolescents by creating an insulin profile that mimics as closely as possible, the 
physiological one is therefore of great importance. This thesis work has focused on the 
long-acting insulin analogs, glargine and detemir, and their effect on metabolic control, 
endogenous insulin production and the GH-IGF-axis, examining all these aspects in 
different studies of children and adolescents with type 1 diabetes.
 2 
2 BACKGROUND - TYPE 1 DIABETES 
2.1  INCIDENCE 
The incidence of type 1 diabetes is not equal throughout the world, being highest in northern 
Europe and lowest in Asia and South America (Patterson, Guariguata et al. 2014). Finland 
(57.6 cases per 100,000 people under 15 years old) and Sweden (43.1 cases per 100,000 
people under 15 years old) have very high incidences. There has been a steady increase in 
incidence during the last fifty years, the steepest rise occurring in children under the age of 
five (Gale 2002; Patterson, Dahlquist et al. 2009). Onkamo et al. reported the world wide 
increase to be 3.0% per year during the period from 1960 to 1996 (Onkamo, Vaananen et al. 
1999), while the increase in Europe for the same time was slightly higher (EURODIAB ACE 
study group 2000). It was later reported the same increase from 1989 to 2008 in all registered 
European countries (Patterson, Gyurus et al. 2012), although several reports from the Nordic 
countries have shown that the increase in incidence seems to have leveled off during recent 
years (Berhan, Waernbaum et al. 2011; Harjutsalo, Sund et al. 2013; Skrivarhaug, Stene et al. 
2014). 
2.2 ETIOLOGY 
Type 1 diabetes is caused by autoimmune destruction (Bottazzo, Cudworth et al. 1978) of the 
insulin-producing beta-cells in the pancreas, influenced by both genetic and environmental 
factors. The lifetime risk of developing type 1 diabetes for the general population is 
approximately 0.4%, and increases if a first-degree relative has the disease. Siblings have 3- 
6% risk of developing type 1 diabetes (Mehers and Gillespie 2008) and the risk for diabetes is 
lower if the mother has diabetes (2.6%) than if the father (5.7%) has the disease (Tuomilehto, 
Lounamaa et al. 1992).  
 
Multiple autoantibodies, have been identified as leading to the autoimmune beta cell 
destruction; glutamic acid decarboxylase antibodies (GADA) (Baekkeskov, Aanstoot et al. 
1990), protein tyrosine phosphatase antibodies ( IA-2A) (Hawkes, Wasmeier et al. 1996) and 
antibodies to insulin (IAA) (Palmer, Asplin et al. 1983). In 2007 another autoantibody was 
identified to be involved in risk of developing type 1 diabetes, antibodies to the Zink 
transporter complex (ZnT8A) (Wenzlau, Juhl et al. 2007).The autoimmune process begins 
early in life and autoantibodies can be detected before one year of age, in children, genetically 
at risk. The incidence of activation of autoimmunity is high between 9 months and 2 years of 
age (Ziegler and Bonifacio 2012). There are high risk HLA types with which the risk of 
developing autoantibodies are three times higher than it is for individuals with moderate risk 
genotypes (Kukko, Virtanen et al. 2004). Different environmental triggers influence the onset 
of type 1 diabetes in genetically predisposed individuals and they are becoming more and 
more important in the disease’s rate of development. In recent years more children with less 
genetic susceptibility have been developing diabetes (Gillespie, Bain et al. 2004; Fourlanos, 
Varney et al. 2008; Resic-Lindehammer, Larsson et al. 2008; Carlsson, Kockum et al. 2012). 
 
Addressing the observation that the environment seems to interact with the development of 
type 1 diabetes earlier in life are some hypotheses about why this happens. One is the hygiene 
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hypothesis, first proposed in 1989 (Strachan 1989), which suggests that, with a decreasing 
number of infections, the immune response is upregulated increasing the risk of allergic and 
autoimmune disorders (Cooke 2009; Kondrashova, Seiskari et al. 2013). Another theory about 
the increased incidence and lower ages for diagnosis is the accelerator hypothesis, which states 
that rapid growth and weight gain causes greater stress on the beta cells and precipitate earlier 
onset of the disease (Kibirige, Metcalf et al. 2003; Wilkin 2012). 
Apart from these theories it has long been thought that the disease process leading to overt 
type 1 diabetes is triggered by an infectious agent. Perhaps the enterovirus acts as an antigen 
and causes inflammation in the gut, thus driving the autoimmune process (Knip and Simell 
2012). Other viruses discussed as possibly associated with type 1 diabetes are rotavirus and 
Ljunganvirus (Nilsson, Vaziri-Sani et al. 2013). Another environmental factor that early on 
was thought to be involved was protection by breastfeeding, but influences seems small 
(Samuelsson, Johansson et al. 1993). Likewise, the time at which cow milk is introduced into 
a child’s diet and the amount of cow milk consumed, have been studied as potentially 
influential factors, but data are conflicting (Dahlquist, Blom et al. 1990). Although a large 
intervention study introducing a cow milk free supplementation after breastfeeding stops for 
children at risk of diabetes has failed to decrease the appearance of diabetes associated 
antibodies (Knip, Akerblom et al. 2014) Finally, a meta-analysis based on five studies has 
shown that supplementation with vitamin D early in life may be associated with lesser risk of 
diabetes (Zipitis and Akobeng 2008). 
2.3 PHYSIOLOGY 
 Insulin and its role in glucose metabolism 2.3.1
Insulin is produced in pancreatic beta cells as proinsulin (Steiner 1969). This molecule is then 
cleaved into insulin and C-peptide; these two molecules are stored and later secreted into 
portal circulation in equimolar concentrations. While insulin is extracted by the liver to a large 
extent, almost all C-peptide reaches the peripheral circulation and can thus be used as a marker 
of endogenous insulin production (Faber and Binder 1986). 
 
Insulin is involved in carbohydrate, protein and lipid metabolism. Regarding glucose, insulin 
enhances transport over the cell membrane, increases the rate of glycolysis, stimulates 
glycogen synthesis and decreases glycogen breakdown. In lipid metabolism, insulin decreases 
lipolysis in adipose tissue and stimulates synthesis of fatty acids and glycerol as well as the 
uptake of triglycerides from the blood into adipose tissue and muscle. In the liver and muscle 
tissues insulin decreases the rate of fatty acid oxidation. Insulin also stimulates uptake and the 
synthesis of protein and is overall therefore an anabolic hormone (Dimitriadis, Mitrou et al. 
2011). 
 
Glucose is moved by several glucose transporters (GLUTs) (Zhao and Keating 2007). GLUT-
2, which is expressed in liver and beta cell, is insulin independent. Glucose entering the cell 
starts a chain reaction, involving closing of ATP-sensitive potassium channels that in turn 
opens calcium channels. The entry of calcium stimulates insulin release into portal circulation 
(Hussain 2008). GLUT-4 is the insulin dependent glucose transporter, present in skeletal 
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muscle and adipose tissue (Birnbaum 1989) and therefore plays a key role in glucose 
metabolism and insulin resistance (Govers 2014).  
 Insulin in relation to the GH-IGF-axis 2.3.2
Insulin interacts with the GH-IGF-axis in two ways in the liver. First it increases sensitivity to 
GH by increasing the expression of the GH receptor (GHR), its downstream signaling and 
thereby the production of IGF-I (Leung, Doyle et al. 2000).Second it down regulates IGFBP-1 
and thus increases the bioavailability of IGF-I (Brismar, Fernqvist-Forbes et al. 1994). 
IGF-I is a polypeptide structurally homologous to insulin that has insulin-like metabolic and 
growth-promoting actions (Daughaday, Phillips et al. 1976; Hall, Bang et al. 1995; Mauras 
and Haymond 2005). IGF-I acts with GH to induce growth via the proliferation and expansion 
of the growth plate (Kaplan and Cohen 2007). In glucose metabolism it acts against GH by 
producing insulin-like effects and increasing glucose uptake in muscles via the IGF type 1 
receptor (IGF-1R) (Dohm, Elton et al. 1990; Crowne, Samra et al. 1998). IGF-I effects in 
adipose tissue and liver are minimal as the IGF-1R is not expressed in significant quantities in 
humans (Bolinder, Lindblad et al. 1987). IGF-I also down regulates GH by negative feedback 
(Yakar, Setser et al. 2004; Clemmons 2006). Complete lack of IGF-I expression in a human 
subject increased insulin needs and lowered insulin sensitivity (Woods, Camacho-Hubner et 
al. 1996). IGF-I and insulin cross-reacts on their respective receptors but these effects are less 
important under most conditions, than are the hypoglycemic effects on their respective 
receptors. It has been suggested that hybrid receptors, composed of one-half insulin receptor 
(IR) and one-half IGF-1R are important for mediating IGF-I effects in muscle (Fernandez, 
Kim et al. 2001). Most of the circulating, metabolically active IGF-I is produced in the liver 
(Yakar, Liu et al. 1999), but IGF-I is also produced locally in most tissues including skeletal 
muscle (Loughna, Mason et al. 1992), adipose tissue (Nam and Marcus 2000), and the growth 
plate (Yakar, Liu et al. 1999), where its contributions to local IGF-I actions are important. 
Unlike insulin, IGF-I is not delivered on demand, but maintains a more stable diurnal level 
caused by its bond to a group of IGF binding proteins (IGFBP)-1-6 (Juul 2003), regulating its 
bioavailability. IGFBP-3 and -5 bind to IGF-I or to IGF-II and then associates with the acid 
labile subunit (ALS) to form large ternary complexes with long half-lives. Binary complexes 
of IGF-I bound to BP-1, 2, 4 and 6 and have shorter half-lives in circulation (Holly and Perks 
2006; Clemmons 2012). 
 
Proteolysis of IGFBP-3 is an important mechanism for increasing the bioavailability of IGF-I 
for peripheral tissues (Bang 1995). This action has been shown to increase in states 
characterized by increased insulin resistance, such as pregnancy (Giudice, Farrell et al. 1990; 
Yan, Payet et al. 2009) and type 2 diabetes (Bang, Brismar et al. 1994). It seems to contribute 
to adaption to insulin deficiency, but not to disturbances in GH secretion that lead to low IGF-I 
secretion (Lassarre, Duron et al. 2001). The protease activity is considerable in healthy 
children at a young age, but decreases with age, reflecting higher levels of IGF-I (Renes, van 
Doorn et al. 2014).  
 
IGFBP-1 is mainly produced in the liver and is particularly interesting in the context of type 1 
diabetes because its production is inversely related to the insulin levels in the portal vein 
(Brismar, Fernqvist-Forbes et al. 1994; Lee, Giudice et al. 1997). It has been established that 
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IGFBP-1 can serve as a marker of portal insulin action or sensitivity (Hilding, Brismar et al. 
1995; Kotronen, Lewitt et al. 2008). Low levels of IGFBP-1 in circulation lead to increased 
levels of IGF-I and may increase the bioactivity of IGF-I in the tissues, although experimental 
proof is lacking (Lewitt, Denyer et al. 1991). 
GH is produced in the pituitary, and secretion is regulated by several factors: glucose, fatty 
acids, and hormones like GH releasing hormone, somatostatin, leptin and ghrelin, in addition 
to the negative feed-back of IGF-I. GH induces insulin resistance (LeRoith and Yakar 2007) 
through several mechanisms, doing so directly by stimulating lipolysis (Williams, Amin et al. 
2003; Vijayakumar, Novosyadlyy et al. 2010), thereby increasing hepatic glucose production 
(HGP) (Salgin, Marcovecchio et al. 2009) and doing so indirectly by interacting with the 
IR/IGF-IR signaling (Dominici, Argentino et al. 2005). 
GH hyper secretion, which occurs during puberty to promote growth, leads to insulin 
resistance (Moller, Jorgensen et al. 1991; Moran, Jacobs et al. 2002). Maximal insulin 
resistance is seen in mid and late puberty, which is Tanner stadium 3 and 4 (Smith, Dunger et 
al. 1989; Caprio, Cline et al. 1994). IGF-I levels are increased in relation to the increased GH. 
Estrogen allows a concomitant rise in GH and IGF-I by relaxing the negative feed-back axis of 
IGF-I (Veldhuis and Bowers 2003). The increase of insulin becomes physiologically 
meaningful by promoting anabolism and linear growth. IGF-I balances the diabetogenic 
effects of GH. Because of the increased levels of insulin IGFBP-1 is decreased during puberty 
in healthy adolescents (Juul, Main et al. 1994). 
 
 
Fig.1. Schematic presentation of interactions between insulin and GH-IGF-axis in normal 
physiology. 
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2.4 PATHOPHYSIOLOGY 
 Insulin deficiency and endogenous insulin production 2.4.1
The biochemical abnormality in type 1 diabetes is insulin deficiency, but the insulin secretion 
from the beta cell must be reduced to almost 10 % before hyperglycemia is induced (Pipeleers 
and Ling 1992; Gorus, Keymeulen et al. 2013). After diagnosis and the start of insulin 
treatment most patients do recover some endogenous insulin production, measured as 
increased C-peptide. The clinical remission with recovery of endogenous insulin production 
peaks at three to six months (Agner, Damm et al. 1987). Differences in insulin sensitivity also 
affect the remission period, and increased insulin sensitivity is shown to precede increased 
beta-cell activity in newly diagnosed type 1 diabetes (Linn, Ebener et al. 1995). Several 
factors, among them season, gender, age, glycosylated hemoglobin (HbA1c) at diagnosis and 
the number of autoantibodies have been shown to affect both the level of C-peptide at 
diagnosis and its decline (Ludvigsson and Hellstrom 1997; Ortqvist, Falorni et al. 1997; 
Ludvigsson, Carlsson et al. 2013; Samuelsson, Lindblad et al. 2013). Age is inversely related 
to a reduction in C-peptide (Ludvigsson, Carlsson et al. 2013) or to the duration of clinical 
remission (Ortqvist, Falorni et al. 1997). C-peptide declined roughly 50% in the first year after 
diagnosis among children, while the first year decline among adults was 20% (Greenbaum, 
Beam et al. 2012). Intensive insulin treatment beginning at diagnosis has been shown to 
improve C-peptide levels and metabolic control for one year or more in both adults (Linn, 
Ortac et al. 1996) and adolescents (Shah, Malone et al. 1989). Several interventions to induce 
beta-cell rest have been conducted. Somatostatin (Bjork, Berne et al. 1998) and diazoxide 
(Ortqvist, Bjork et al. 2004) have both been shown to induce prolonged endogenous insulin 
production via temporary beta-cell rest but neither has come into clinical use owing to 
unwanted side-effects.  
Different kinds of immunomodulation to prevent beta cell destruction have been tested. 
Cyclosporine was reported to induce beta-cell rest in the 1990’s (Skyler and Rabinovitch 
1992), but was never used because of severe adverse reactions. In later years clinical trials of 
immunotherapy directed toward lymphocytes using anti-CD3 (teplizumab or otelixizumab) 
and anti-CD20 (rituximab) resulted in transient insulin secretion (Coppieters, Harrison et al. 
2013). More antigen-specific agents such as GAD65 alum have been tested in children and the 
first study indicates that beta-cell capacity could be preserved (Ludvigsson, Faresjo et al. 
2008) in children recently diagnosed with type 1 diabetes, although this could not be repeated 
in a second larger trial (Ludvigsson, Krisky et al. 2012). Anti-cytokine therapies blocking IL-
1, IL-6 and tumor necrosis factor have also been tried (Nepom, Ehlers et al. 2013). Anti-
oxidants, including nicotinamide and vitamin E (Pozzilli, Visalli et al. 1997) have been 
investigated and more recently the use of vitamin D was proposed (Ludvigsson 2012). All 
immunomodulation efforts and future perspectives in this area were recently summarized in a 
review (Lord and Greenbaum 2015).  
A follow-up of the DCCT study has shown that a stimulated C-peptide level of > 0.2 nmol/l at 
study inclusion was important both for delaying vascular complications and for reducing the 
risk of hypoglycemic episodes (Steffes, Sibley et al. 2003). A recent, more thorough analysis 
of the same data has revealed that there is a near-linear regression with no threshold in the 
decline of C-peptide, in addition very small amounts of remaining C-peptide seems to be of 
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great importance (Lachin, McGee et al. 2014). In the “medalist study” some subjects who had 
been living with diabetes for over 50 years were still C-peptide positive (Keenan, Sun et al. 
2010).  
 Insulin deficiency in relation to the GH-IGF-axis 2.4.2
Type 1 diabetes causes deleterious changes in the GH-IGF-axis (Dunger and Cheetham 1996). 
Subjects with type 1 diabetes treated with subcutaneous insulin injections have a portal insulin 
deficiency, which affects hepatic GHR function (Baxter, Brown et al. 1980), as a result of a 
decreased number of GHRs (Menon, Arslanian et al. 1992) and post receptor defects in GH 
action (Maes, Underwood et al. 1986; Hanaire-Broutin, Sallerin-Caute et al. 1996). This 
impaired GH action leads to decreased levels of both circulating total and free IGF-I (Taylor, 
Dunger et al. 1988; Frystyk, Bek et al. 2003; Hedman, Frystyk et al. 2004). The low levels of 
IGF-I create a lack of negative feedback and consequently GH secretion increases, leading to 
greater insulin resistance (Dunger, Cheetham et al. 1995; Frystyk 2004). Insulin administration 
at diagnosis of type 1 diabetes increases GH binding protein (GHBP, a marker of hepatic GHR 
numbers. This further underlines the importance of insulin in regulating the GHR. However, 
GHBP levels remain subnormal (Arslanian, Menon et al. 1993). The portal insulin deficiency 
also causes increased IGFBP-1 levels in both children and adolescents (Hall, Johansson et al. 
1989; Radetti, Paganini et al. 1997) and adults (Suikkari, Koivisto et al. 1988; Ekman, 
Nystrom et al. 2000). IGFPB-3 and ALS are decreased although some IGFBP-3 
immunoassays may detect an increase (Diamandi, Mistry et al. 2000), since IGFBP-3 
proteolysis is increased in adolescents with type 1 diabetes (Zachrisson, Brismar et al. 2000). 
IGF-I levels are low in both prepubertal (Salardi, Cacciari et al. 1986; Strasser-Vogel, Blum et 
al. 1995) and pubertal (Zachrisson, Brismar et al. 1997) children with type 1 diabetes. 
Glycemic control has been shown to affect IGF-I levels in diabetic subjects during puberty, 
but not before (Rogers, Sherman et al. 1991). In one study age-adjusted values for IGF-I 
correlated inversely with HbA1c (Strasser-Vogel, Blum et al. 1995). 
 
Fig.2. Schematic presentation of changes in GH-IGF-axis in type 1 diabetes when endogenous 
insulin secretion is replaced by subcutaneous insulin injections. 
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Bereket et al., who studied children and adolescents before and after the initiation of insulin 
therapy, found that IGF-I was very low (75 % less) at diagnosis, but increased one week after 
the initiation of insulin treatment. IGFBP-1 levels were elevated up to sevenfold, and 
decreased within 24 hours after the first insulin dose (Bereket, Lang et al. 1995). The decrease 
in IGFBP-1 led to increased free IGF-I (Bereket, Lang et al. 1996) preceding the increase of 
circulating IGF-I, suggesting that IGFBP-1 plays a role in the acute regulation of glucose 
metabolism and interacts with the glucose rise at dawn (Cotterill, Daly et al. 1995; Kobayashi, 
Amemiya et al. 1997). Before insulin initiation Bereket et al. also found that IGFBP-3 
proteolysis was increased but reversed by insulin treatment, thus suggesting that insulin 
regulates this proteolysis activity and may help to counteract the catabolic state induced by 
severe insulin deficiency (Bereket, Lang et al. 1995). 
 
Intra-peritoneal delivery of insulin can restore the decreased IGF-I levels (Hanaire-Broutin, 
Sallerin-Caute et al. 1996; Hedman, Frystyk et al. 2014), but only intra-portal delivery of 
insulin can induce a complete restoration of the changes in the GH-IGF-axis (Shishko, Dreval 
et al. 1994).  
During puberty GH levels are even more increased in subjects with type 1 diabetes than in 
healthy subjects (Amiel, Sherwin et al. 1986; Dunger and Acerini 1998). This is shown to be 
more prominent in girls and does not affect only nightly GH secretion (Halldin, Tylleskar et 
al. 1998). Circulating IGF-I is lower (Zachrisson, Brismar et al. 1997), and IGFBP-1 is further 
increased (Zachrisson, Dahlquist et al. 2000), leading to increased insulin resistance and often 
to deteriorated metabolic control (Acerini, Williams et al. 2001). Increased IGFBP-3 
proteolytic activity (IGFBP3-PA) is also present and may play a compensatory role in 
attenuating the decreased free IGF-I and thus to some extent increasing insulin sensitivity and 
restoring glycemic control (Zachrisson, Brismar et al. 2000). 
 
Components in 
GH-IGF-axis 
Type 1 diabetes 
Prepuberty 
 
Puberty 
 
GH   
IGF-I   
IGFBP-1   
IGFBP3-PA   
 
Table 1: Changes in serum concentration of components in the GH-IGF-axis in type 1 diabetes, before and during puberty, 
compared to healthy subjects. 
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2.5 METABOLIC CONTROL AND LONG-TERM COMPLICATIONS 
In healthy humans, glucose levels are kept in a narrow physiological interval of approximately 
3.5-7 mmol/l by insulin, which is by instant feedback secreted into the portal vein in response 
to the plasma glucose level. In diabetes the goal of treatment is to keep the blood glucose 
levels as normal as possible. Hyperglycemia causes increased oxidative stress (Chung, Ho et 
al. 2003) and inflammation and is thereby toxic for the endothelial cells (Lorenzi, Toledo et al. 
1987). The long-term result of this damage is both micro and macro vascular complications. 
The most vulnerable vessels are those in the kidney (de Boer 2014) and those in the retina 
(Aiello 2014).  
 
The DCCT, in which conventional insulin therapy, using one or two daily injections, was 
compared to intensive insulin treatment, using three or more daily injections or an insulin 
pump (CSII) showed the importance of maintaining good metabolic control in order to prevent 
and delay long-term micro vascular complications (DCCT 1993). The follow up study of the 
DCCT, dubbed the Epidemiology of Diabetes Interventions and Complications (EDIC) study 
demonstrated that there is a “metabolic memory” (Nathan 2014), meaning that good metabolic 
control in early years after diagnosis is remembered despite later deterioration. This can be 
explained by the glycosylation of mitochondrial proteins (Ceriello 2009). Furthermore 
intensive insulin treatment in the DCCT for subjects with remaining C-peptide was shown to 
increase endogenous insulin production (DCCT 1998). 
 
In a Swedish follow-up examining a group of adults with type 1 diabetes who had been 
diagnosed in childhood and who had been living with diabetes for at least 15 years, the 
diabetes duration and long-term HbA1c were both risk factors for developing retinopathy and 
nephropathy (Nordwall, Arnqvist et al. 2009). In a recent long-term follow up study, no one 
with a long-time HbA1c below 7,6% (DCCT) (60 mmol/mol) had developed severe 
retinopathy or nephropathy (Nordwall, Abrahamsson et al. 2015). Another Swedish 
population based study showed that despite intensive insulin therapy about half the patients 
developed microvascular complications after 12 years. Inadequate HbA1c during the first 
years accelerated the complications, although young age at diagnosis delayed the incidence 
(Svensson, Eriksson et al. 2004). A recent follow up using two Swedish diabetes registers 
show that metabolic control during the first year after diagnosis in children influences the risk 
of developing retinopathy and microalbuminuria in early adult years (Samuelsson, Steineck et 
al. 2014). 
2.6 MEASUREMENTS OF METABOLIC CONTROL 
HbA1c has been considered the main measurement of long-term metabolic control. In recent 
years, however, it has been suggested that glucose variability also contributes to the 
development of long-term complications. Data are conflicting and the clinical correlates 
detected so far are limited (Cavalot 2013), although both experimental (Ceriello, Esposito et 
al. 2008) and clinical studies (Monnier, Colette et al. 2010) have shown that both long-term 
stable hyperglycemia and intermittent hyperglycemia over the short and the long-term induce 
oxidative stress that causes vascular damage (Saisho 2014). In a Swedish study of adults with 
type 1 diabetes glycemic variability was shown to possibly predict the development of long-
term neuropathy (Bragd, Adamson et al. 2008). 
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 HbA1c 2.6.1
The glycosylation of hemoglobin is a non-enzymatic, irreversible reaction affecting 
hemoglobin and other proteins exposed to glucose. Since the erythrocyte normally has a 
lifespan of 120 days, the degree of glycosylation reflects in practice the average glucose 
concentration over the last two to three months. In conditions with increased turnover of 
erythrocytes, such as thalassemia and hemolytic anemia, false low values may be obtained in 
the measurement of HbA1c (Landin-Olsson, Jeppsson et al. 2010). 
 
 
There are several standards in measuring HbA1c. In 
Sweden the Mono-S method was used until 2010, but 
was approximately 1% unit lower than the National 
Glycohemoglobin Standardization Program 
(NGSP)/DCCT standard, used worldwide. To 
coordinate all measures it was agreed in October 2010 
to use a new worldwide standard – the International 
Federation of Clinical Chemistry and Laboratory 
Medicine (IFCC) (Hanas and John 2010). The IFCC 
values are reported in mmol/mol.  
 
 
 Glucose variability 2.6.2
The first and basal way to measure glucose is through self-monitoring of blood glucose 
(SMBG). A relation between the numbers of SMBG events per day and HbA1c reduction has 
been described (Schutt, Kern et al. 2006). But SMBG provides only intermittent single blood 
glucose levels, most often only during the day, without giving a 24 hour view. Continuous 
glucose monitoring (CGM) can for this purpose be very helpful. Blinded CGM, where no 
measures are shown in real time, can be used in research and “real time” CGM, where the 
glucose values can be followed continuously, is becoming a routine method. Use of “real-
time” CGM has been shown to improve HbA1c in both children and adults (Battelino, Phillip 
et al. 2011). 
Several factors are important regarding glucose variability; among them are time, glucose 
level and amplitude. The most direct way to monitor glucose variability is to use the mean 
value of glucose derived either from SMBG or from CGM. The standard deviation (SD) of the 
mean is often used as a measurement of glucose variability, although it does not evaluate 
whether the observed deviations represent hypoglycemia or hyperglycemia (Kovatchev, Cox 
et al. 2002). Mean blood glucose levels have been shown to correlate to HbA1c (Sacks 2007). 
Besides the simple mean and SD of mean, several mathematical methods may be used to 
estimate glucose variability. One is the Mean Amplitude of Glycemic Excursions (MAGE), 
first described in 1970 (Service, Molnar et al. 1970) from continuous glucose venous 
Mono-S 
HbA1c 
(%) 
DCCT 
HbA1c  
(%) 
IFCC 
HbA1c 
(mmol/mol) 
4.0 5.0 31 
4.5 5.5 36 
5.0 6.0 42 
5.5 6.4 47 
6.0 6.9 52 
6.5 7.4 57 
7.0 7.9 63 
8.0 8.8 73 
9.0 9.8 83 
10.0 10.7 94 
12.0 12.7 115 
Table 2: Comparison between Mono-S, DCCT and 
IFCC standard for HbA1c. 
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sampling. It constitutes of all glucose variations above one standard deviation. There are two 
possible advantages with MAGE, first it measures major glycemic swings but excludes minor 
ones and second it is not dependent on the glucose mean (Monnier, Colette et al. 2008). 
Several studies have shown that HbA1c is positively associated with MAGE and it is still used 
as a reliable index of glucose variability (Ferenci, Korner et al. 2015). Other variability 
indexes are the M-value (Schlichtkrull, Munck et al. 1965) and day-to-day glycemic variations 
of excursions (MODD) (Molnar, Taylor et al. 1972). Low blood glucose and high glucose 
index are also often reported. Which glucose variability index is superior and should be used is 
still debated (Service 2013). 
2.7 TREATMENT OF TYPE 1 DIABETES 
 Historical aspects 2.7.1
Insulin was discovered in 1921 by Frederic Banting, Charles Best, and their co-workers from a 
pancreas extract. It was first tested on a severely ill teenager, Leonard Thompson, in 1922 
(Herrington 1995). The first injection was complicated by a severe allergic reaction, but after 
further purification of the insulin the treatment became a success and several dying children 
could be treated. The researchers were rewarded the Nobel Prize in 1923 for this life saving 
development. 
After this landmark, insulin preparations were manufactured and insulin therapy spread. From 
the beginning insulin was extracted from bovine pancreas. A major problem was the short 
duration of the effects of water soluble insulin preparations. The first insulin, with prolonged 
duration, was protamine zinc insulin, developed in the 1930s. In the 1940s NPH insulin was 
developed in Denmark, but all insulin was still extracted from animals. It was not until the 
1980s, that human insulin was produced, following advances in molecular biology (Levinson 
2003). During the last 20 years hybrid DNA process has made it possible to refine products 
and modified insulin analogs have been developed. 
 Different insulin regimens 2.7.2
In healthy humans, insulin is secreted in a pulsatile manner to meet the increased need after 
meals and maintaining a basal level of about 50 % of total insulin secretion (Polonsky, Given 
et al. 1988).The goal in treating type 1 diabetes is to mimic the physiological release of 
insulin, which is characterized by a stable basal level that peaks in response to meals (Owens, 
Zinman et al. 2001). By administrating insulin subcutaneously it is difficult to mimic the 
physiological release because of a variable insulin uptake from the subcutaneous fat and often 
great day-to day variability (Lepore, Pampanelli et al. 2000). Before 1970 most patients with 
type 1 diabetes were treated with insulin twice daily. Since then multiple injection therapy 
(MIT) with NPH insulin as basal component and short-acting insulin before meals became 
more common and resulted in an improved metabolic control in many patients (Eschwege, 
Guyot-Argenton et al. 1976). However, the imitation of physiological insulin release was still 
poor and to address this problem, insulin analogs were developed using a DNA-recombinant 
technique. First developed were two short-acting insulin analogs, lispro and aspart, with faster 
absorption than regular human insulin and hence improved postprandial blood glucose levels 
(Bolli, Di Marchi et al. 1999; Heise 2007). But there remained a need for a basal insulin that 
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was more stable and reproducible than NPH (Heise and Pieber 2007). For this purpose the two 
long-acting insulin analogs, glargine and detemir, with a time profile of nearly 24 hours were 
developed. Today the most widely used insulin regimen among children and adolescents with 
type 1 diabetes in Sweden is MIT, also called the basal-bolus regimen, which entails multiple 
injections per day of meal boluses, of a rapid-acting analog together with one or two injections 
of basal insulin. Another way to more closely mimic the physiological release is through 
subcutaneous continuously insulin infusion (CSII), insulin pump, which is used by 
approximately 50 % of children and adolescents in Sweden (Swediabkids year report 2014).  
Although the regimens for subcutaneous insulin delivery aim to match the body’s insulin need 
it is impossible to mimic physiological insulin secretion perfectly, since insulin is delivered to 
the portal system in humans rather than into peripheral circulation. Subcutaneously injected 
insulin reaches the portal region only to a limited extent (Rachmiel, Perlman et al. 2005). 
Insulin type Appearance Onset Peak Duration 
Fast-acting insulins Clear 0.5–1 2–5 6-8 
Rapid-acting analogs (aspart, glulisin, 
lispro) 
Clear 5–10 min  0.5–2 3–4 
Intermediate-acting insulin e.g. NPH Cloudy 1–3 5–8 12–18 
Long-acting analogs (glargine, detemir) Clear 1.5–4 None 20–24 
Ultra-long-acting analog (degludec) Clear  None > 40 
Table 3: Characteristics of different insulins (time in hours unless given). Modified from Rachmiel et al. 2005. 
 Basal insulins - pharmacological aspects 2.7.3
My thesis work has focused on the effects of long-acting insulin analogs in comparison to 
intermediate-acting NPH insulin. The first long-acting insulin analog to enter the market was 
insulin glargine (Lantus®) in 2000 (Bolli and Owens 2000). In 2004 another long-acting 
insulin analog, insulin detemir (Levemir®) was introduced in Europe, in 2005 it was approved 
for use in children (EMA assessment report 2011). Both glargine and detemir have lower 
peaks and longer durations than NPH does (Rachmiel, Perlman et al. 2005). Recently, the 
ultra-long-acting insulin, degludec (Tresiba®) was introduced and in February 2015 it was 
approved for use in children. It is almost identical to human insulin, but with small amino acid 
changes and a link to a fatty acid (Rendell 2013). The formation of multi hexamer chains in 
subcutaneous fat yields a duration of > 40 hours in both adults and children (Biester, Blaesig 
et al. 2014). Degludec had not yet been introduced when the studies in my thesis were planned 
and therefore was not included in my comparison, but may be of interest in future research 
projects. 
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 NPH insulin - intermediate-acting insulin 2.7.3.1
NPH insulin is a crystal preparation with reduced solubility at physiological pH, resulting in 
slower absorption from the subcutaneous tissue (Owens, Zinman et al. 2001). This absorption 
is highly variable. Because of the peak between five and eight hours after injection, which is 
attenuated with increased dosing, there is a risk of night-time hypoglycemia (Rachmiel, 
Perlman et al. 2005). These pharmacological properties contributes to unsatisfactory control of 
fasting-glucose (Lepore, Pampanelli et al. 2000), especially among adolescents, who show 
insulin resistance during late night, because of increased levels of GH (Edge, Matthews et al. 
1990). 
 
The late night under insulinization that accompanies NPH treatment results in increased levels 
of IGFBP-1and in decreased free IGF-I and may contribute to greater insulin resistance 
(Yagasaki, Kobayashi et al. 2010). 
 Insulin glargine – long-acting insulin analog 2.7.3.2
Glargine is produced by recombinant DNA technology. The structure is different from human 
insulin in three amino acids (Wang, Carabino et al. 2003). This modification results in a 
delayed onset and a longer duration. Glargine has normal solubility in the preparation owing 
to its slightly acidic pH while it forms crystals and precipitates at the neutral subcutaneous pH 
(Bolli and Owens 2000; Rachmiel, Perlman et al. 2005). This leads to a more stable diurnal 
release of insulin into circulation without pronounced peaks and produces an action time of 
approximately 24 hours (Lepore, Pampanelli et al. 2000).  
Glargine binds to both the IR and the IGF-1R, because of this, concerns have arisen about 
whether glargine could have mitogenic actions (Kurtzhals, Schaffer et al. 2000). This opinion 
is not supported in studies on cell lines, using in vivo concentrations of glargine (Chisalita and 
 
Fig.3. Schematic presentation of the changes in the GH-IGF-axis when NPH is used for basal 
insulin supplementation in puberty. 
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Arnqvist 2004). Furthermore glargine is converted into two metabolites in the subcutaneous 
fat, M1 and M2. These metabolites have similar glucose lowering effects but less growth 
promoting actions (Sommerfeld, Muller et al. 2010). 
 Insulin detemir – long-acting insulin analog 2.7.3.3
Detemir, like glargine, has been developed using recombinant DNA technology and is a 
soluble preparation. It differs from human insulin by one amino acid and an acetylated fatty 
acid. Its duration is prolonged, primarily because of slow absorption into the blood that results 
from self-association and albumin binding (Kurtzhals 2007). After a single dose of 0.4 U/kg 
the duration of action was shown to be 22-24 hours (Lepore, Pampanelli et al. 2000). One 
clamp study in adults with type 1 diabetes did, however, show that detemir had a duration of 
only 17.5 hours at a dose of 0.35 U/kg in contrast to glargine’s 24 hours of action (Porcellati, 
Rossetti et al. 2007). In a review of several clamp studies comparing glargine’s and detemir’s 
duration Heise et al. considered the shorter duration of detemir in Porcellati’s study an outlier 
(Heise and Pieber 2007). Detemir has been associated with significantly less within-subject 
variability than both NPH and glargine (Heise, Nosek et al. 2004). In a clamp study of healthy 
adults detemir, compared to NPH in equipotent doses, had a lesser effect on suppressing 
lipolysis in peripheral tissue, but a higher effect on glucose metabolism in the liver than NPH 
(Hordern, Wright et al. 2005), which might explain why detemir is associated with less weight 
gain than NPH (Home, Bartley et al. 2004; Russell-Jones, Simpson et al. 2004). Detemir is 
also shown to have a molar ratio of 5:1 compared to NPH in healthy individuals (Hordern, 
Wright et al. 2005) and also a higher molar ratio compared to glargine (Porcellati, Bolli et al. 
2011). This molar difference is, however, compensated for in one unit of detemir in the 
manufactured preparation, Levemir® (Owens and Bolli 2008). 
 Studies comparing long-acting insulin analogs 2.7.4
A recent systematic review and network meta-analysis of studies comparing long-acting 
analogs to NPH used to treat adults with type 1 diabetes concluded that long-acting insulin 
analogs are superior to intermediate-acting insulin analogs, the difference in HbA1c is 
although small (Tricco, Ashoor et al. 2014). In a meta-analysis of randomized controlled 
(clinical) trials (RCTs) comparing both glargine and detemir to NPH , the long-acting analogs 
showed a small, but significantly better effect on HbA1c and a reduced risk of severe and 
nocturnal hypoglycemia (Monami, Marchionni et al. 2009). It included mostly studies of 
adults, but three studies had examined children and adolescents. The effects of the long-acting 
analogs, on children and adolescents, are not entirely clear and depend on study design and the 
length of study period. Table 4 shows selected RCTs comparing glargine or detemir with 
NPH. 
 Studies comparing glargine and NPH 2.7.4.1
Several RCTs have compared glargine and NPH for treating type 1 diabetes in adults (Ratner, 
Hirsch et al. 2000; Porcellati, Rossetti et al. 2004; Fulcher, Gilbert et al. 2005; Home, 
Rosskamp et al. 2005; Chatterjee, Jarvis-Kay et al. 2007). Three of them show lower HbA1c 
and lower fasting-glucose with glargine (Porcellati, Rossetti et al. 2004; Fulcher, Gilbert et al. 
2005; Chatterjee, Jarvis-Kay et al. 2007). Only one was performed over a longer period of one 
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year (Porcellati, Rossetti et al. 2004) and also reports a lower incidence of over-all 
hypoglycemia with glargine. All studies were performed on subjects who had been diagnosed 
with diabetes several years earlier. None of them show any difference between glargine and 
NPH in terms of insulin-dose or weight gain. 
Four RCTs have compared glargine and NPH in children and adolescents (Schober, Schoenle 
et al. 2002; Murphy, Keane et al. 2003; Chase, Arslanian et al. 2008; Hassan, Rodriguez et al. 
2008). Only one of them reported lower HbA1c in children recently diagnosed with type 1 
diabetes and studied for not more than three months (Hassan, Rodriguez et al. 2008). Schober 
et al. failed to show lower HbA1c, but found decreased fasting-glucose after 26 weeks. In a 
crossover study performed for 2 × 16 weeks Murphy et al. found a lower incidence of 
nocturnal hypoglycemia and lower fasting-glucose. Chase et al. found no overall differences in 
HbA1c, but did report an improvement with glargine versus NPH in a subgroup of adolescents 
with high HbA1c. In non-randomized, mostly retrospective studies of children and adolescents 
with ongoing type 1 diabetes the data on HbA1c are diverse (Chase, Dixon et al. 2003; 
Hathout, Fujishige et al. 2003; Tan, Wilson et al. 2004; Alemzadeh, Berhe et al. 2005; Colino, 
Lopez-Capape et al. 2005). Some studies show lower HbA1c, but several find improved 
fasting-glucose and less nocturnal hypoglycemia. Furthermore insulin regimens and 
observational times vary between studies. Therefore reliable interpretations are difficult to 
make. One study included subjects at the time of diagnosis of type 1 diabetes and found lower 
HbA1c with glargine (Adhikari, Adams-Huet et al. 2009). 
  Studies comparing detemir and NPH 2.7.4.2
Several randomized studies have compared detemir and NPH in adults over periods ranging 
from 16 to 52 weeks (Vague, Selam et al. 2003; Home, Bartley et al. 2004; Russell-Jones, 
Simpson et al. 2004; Standl, Lang et al. 2004; De Leeuw, Vague et al. 2005). Only Home et al. 
showed improved metabolic control in a 16 weeks RCT. Although the glucose variability and 
the prevalence of hypoglycemia were lower in most studies, only two showed lower fasting-
glucose (Home, Bartley et al. 2004; Russell-Jones, Simpson et al. 2004). All the reported 
studies showed less weight gain with detemir. 
For children and adolescents comparisons of detemir and NPH have failed to demonstrate 
improved HbA1c (Robertson, Schoenle et al. 2007; Thalange, Bereket et al. 2013). Both 
studies showed less nocturnal hypoglycemia and less BMI-gain with detemir and one study 
showed lower fasting-glucose (Robertson, Schoenle et al. 2007). No difference in insulin dose 
was seen. Two observational studies have reported better HbA1c in children on detemir than 
among those on NPH over a limited time. One examined the cohort of Turkish children 
(Kurtoglu, Atabek et al. 2009) in a large multinational observational study of both type 1 and 
type 2 diabetes comparing detemir with NPH over 14 weeks. The other, a multicenter study 
from Japan (Jinno, Urakami et al. 2012), showed lower HbA1c at 3 and 6 months, but no 
difference after 12 months. 
 Studies comparing glargine and detemir 2.7.4.3
Two RCTs of adults with type 1 diabetes compared the two long-acting analogs and found no 
differences in HbA1c after 26 weeks (Pieber, Treichel et al. 2007) or 52 weeks (Heller, 
Koenen et al. 2009). The 26-week parallel comparison showed lower fasting-glucose with 
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glargine, but less risk of nocturnal hypoglycemia and higher insulin doses with detemir. There 
were no differences regarding within-subject variation or weight gain (Pieber, Treichel et al. 
2007). For children, a retrospective observational study showed no differences between 
glargine and detemir, except for higher doses with detemir (Abali, Turan et al. 2014). 
 Studies comparing CSII and NPH or long-acting analogs 2.7.4.4
Data on the advantages of CSII treatment over long-acting analogs and NPH are conflicting, 
probably because they compare different treatment strategies. A fairly recent Cochrane 
Review, comparing CSII to MIT with either NPH or analogs, performed in all age groups, 
stated that there is some evidence for the effectiveness of CSII (Misso, Egberts et al. 2010). A 
meta-analysis in children showed a small positive effect with CSII versus MIT (Pankowska, 
Blazik et al. 2009) and only one of the included studies reported improved HbA1c with CSII 
versus glargine (Doyle, Weinzimer et al. 2004). A more recent study in children showed no 
beneficial effects with CSII versus glargine on HbA1c (Starkman, Frydman et al. 2011) and an 
RCT comparing CSII and MIT with NPH in children, from diagnosis likewise showed no 
difference (Skogsberg, Fors et al. 2008). However two retrospective studies showed a greater 
reduction in HbA1c when changing treatment from NPH to CSII than when moving from 
NPH to glargine (Alemzadeh, Ellis et al. 2004; Schiaffini, Ciampalini et al. 2005). Over the 
long-term (two years) one retrospective study of children comparing CSII to glargine reported 
equal metabolic control (Garcia-Garcia, Galera et al. 2007) and another report from our group, 
comparing CSII and MIT with either NPH or long-acting analog showed lower HbA1c at 12 
months with CSII, but after two years the difference had diminished (Brorsson, Viklund et al. 
2014). 
 Studies comparing long-acting analogs and degludec 2.7.4.5
A meta-analysis of available trials showed a statistically significant reduction in the basal 
insulin dose in the degludec group compared to groups treated with long-acting analogs. There 
was also a significant reduction of nocturnal hypoglycemia in the degludec treated group but 
no differences between the groups in terms of HbA1c, fasting-glucose or adverse events 
(Dzygalo, Golicki et al. 2014). One RCT examining children over 26 weeks showed a 
comparable effect on HbA1c with degludec versus detemir, while fasting-glucose and insulin 
dose were lower with degludec (Thalange, Deeb et al. 2015). 
 
 
Table 4 (On page 17) 
RCTs comparing long-acting insulin analogs (ANA), glargine (GL) or detemir (DT) vs. NPH, in adults or 
children and adolescents with type 1 diabetes. HbA1c is given as DCCT standard (%),*mean or ANA/NPH,   
nr = not registered, ns = non-significant. For hypoglycemia, BMI/body weight (BW), and insulin dose, 
differences at end-point between GL/DT and NPH are given. 
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Reference 
Name and 
year 
Age* 
years 
Duration* 
years 
Study 
design 
weeks 
Regimen 
Numbers 
included 
ANA/NPH 
HbA1c* 
Baseline  
HbA1c  
Endpoint  
ANA/NPH 
P = 
f-glucose* 
Baseline 
mmol/l 
f-glucose 
Endpoint  
ANA/NPH 
P = 
Hypo- 
glycemia 
P 
CGM 
use 
BMI or 
BW 
P 
Insulin 
dose 
RCTs comparing glargine and NPH  in adults 
Chatterjee 
2007 
42.9 18.2 16x2  
cross over 
MIT, GL x1 vs. 
NPHx2 
60/60 8.5 8.1/8.3 0.04 11.5 8.4/11.4 <0.01 ns yes ns ns 
Porcellati 
2004 
35.0 14.0 52  MIT, GL x1 vs. 
NPHx4 
61/60 7.1 6.7/7.1 <0.05 nr 6.7/7.5 0.05 <0.05 no ns ns 
Fulcher 
2005 
40.5 17.5 30 MIT, GL x1 vs. 
NPHx1 
62/63 9.2/9.7 8.3/9.1 0.009 11.2/11.4 -3.5/ 
-2.3 
0.03 Severe 
hypo,0.05 
no ns ns 
Home 
2005 
39.0 16.0 28 MIT, GL x1  
vs. NPH x1- 2 
292/293 7.9 -0.2/-0.1 ns 9.3 -0.8/ 
 -0.8 
ns ns no nr ns 
Ratner 
2000 
38.5 17.4 28 MIT, GL x1 vs. 
NPHx1-2 
264/270 7.7 7.5/7.5 ns 11.8 -1.7/ 
-0.3 
0.01 Severe 
hypo,0.03 
no nr ns 
RCTs comparing detemir and NPH in adults 
Vague 
2003 
40.0 17.2 26 MIT, DT x2 vs. 
NPHx2 
301/146 8.1/8.2 7.6/7.6 ns 11.6 9.2/9.9 ns Noct.hypo 
<0.005 
no <0.001 ns 
Russell-Jones 
2004 
40.5 17.0 26 MIT ,DTx1 vs. 
NPHx1 
491/256 8.4 8.3/8.4 ns 11.9/11.6 10.3/11.4 0.001 Noct.hypo 
0.003 
yes 0.024 ns 
Standl  
2004 
41.0 16.0 52 MIT, DT x2 vs. 
NPH x2 
154/134 7.7 7.9/7.8 ns 10.9 10.1/9.8 ns ns no 0.002 ns 
Home  
2004 
40.0 17.0 16 MIT, DTx2 
vs. NPHx2 
276/132 8.6 7.75/7.9 0.027 11.6/12.2 9.3/11.2 <0.001 0.002 yes Lower DT ns 
De Leeuw 
2005 
40.5 17.1 52 MIT, DT x2 vs. 
NPH x2 
216/99 8.2/8.0 7.5/7.6 ns 11.9/11.5 10.7/10.8 ns Noct.hypo, 
0.016 
no <0.001 ns 
RCTs comparing  glargine and NPH in children and adolescents 
Hassan 
2008 
11.0 0.3 12 Not MIT, GL 
x2 vs. NPHx2 
23/19 6.8/6.9 6.7/7.6 0.029 6.6/7.2 5.7/9.6 0.008 ns no ns ns 
Schober 
2002 
11.6 4.8 26 MIT, GL x1 vs. 
NPH x1-2  
174/175 8.5/8.8 8.8/9.1 ns 10.8/10.6 9.5/9.9 0.02 ns no nr ns 
Chase 
2008 
13.3 5.3 24 MIT, GL x1 vs. 
NPH x2 
84/84 7.8/8.0 -0.25/0.05 ns 10.4/11.3 -0.2/0.05 ns ns no nr ns 
Murphy 
2003 
14.8 7.3 16x2 
crossover 
MIT, GL x1 vs. 
NPH x1 
25 
crossover 
9.3 8.7/9.1 ns 9.8 8.0/9.2 <0.001 Noct.hypo 
<0.05 
no ns Lower  
w. GL 
RCTs comparing detemir and. NPH in children and adolescents 
Robertson 
2007 
11.8 5.0 26 MIT, DTx1-2 
vs. NPH x1- 2 
232/115 8.8/8.7 8.0/7.9 ns 11.2/11.1 8.4/9.6 0.022 Noct.hypo 
0.011 
no <0.001 ns 
Thalange 
2013 
9.9 3.7 52 MDI, DTx1-2 
vs. NPH x1-2 
177/170 8.4 8.7/8.6 ns 8.5 0.02/-0.6 ns Noct.hypo 
0.001 
no <0.001 ns 
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3 HYPOTHESIS AND AIMS 
Hypothesis 
Treatment with long-acting insulin analogs, glargine or detemir, in children and adolescents 
with type 1 diabetes results in better metabolic control, increased endogenous insulin 
production, and normalization of the GH-IGF-axis. 
Specific aims 
Paper I 
To study the effect of changing from NPH to glargine, on the GH-IGF-axis and its 
association with metabolic control in adolescents with type 1 diabetes. 
Paper II 
To retrospectively study if treatment with glargine compared to NPH from the onset of type 
1 diabetes in children and adolescents results in lower HbA1c during the first year of 
disease. 
Paper III 
To prospectively study if randomization to treatment with glargine or detemir compared to 
NPH, from the onset of type 1 diabetes in children and adolescents, results in lower HbA1c, 
decreased glucose variability and better preserved endogenous insulin production during 
the first year of disease. 
Paper IV 
To study if lower HbA1c in paper III is related to normalization of the GH-IGF-axis, 
including increased IGF-I and decreased IGFBP-1, a marker of hepatic insulin action. 
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4 SUBJECTS AND METHODS 
 
Paper Group n 
Age  
yrs 
 (range) 
Sex 
F/M 
Diabetes 
duration 
 yrs (range) 
HbA1c 
 % 
 (mmol/mol) 
Study 
duration 
I 
Pubertal 
NPH->Glargine 
12 
12.7     
(11.1-15.0) 
8/4 3.1 (1.0-6.0) 
8.3±0.6 
(76.1±6.3) 
12 weeks 
II 
NPH 49 
12.0       
(9.0–16.0) 
18/31 
 
From diagnosis 
9.6 ± 2.2* 
(89.7±23.0) 
12 months 
Glargine 49 
12.5       
(8.0–17.0) 
21/28 
11.0 ± 2.3* 
(104.3±24.1) 
III+IV 
NPH 
prepubertal 12 
9.2               
(7-11) 
3/9 
From diagnosis 
108.7±6.3 
12 months 
pubertal 16 
13.8          
(10-17) 
6/10 100.3±4.5 
Glargine  
 
prepubertal 18 
9.2               
(7-11) 
6/12 93.5±3.8 
pubertal 12 
13.5           
(12-15) 
4/8 111.5±4.7 
Detemir    
 
prepubertal 17 
9.1           
(7-11) 
5/12 95.6±4.0 
pubertal 17 
13.7         
(10-17) 
7/10 107.6±6.7 
Table 5: Subjects characteristics at baseline. Data are given as mean±SE (* ±SD) and range for age and 
diabetes duration. HbA1c is given in Mono-S standard, % and (IFCC, mmol/mol) for paper I and II, in IFCC, 
mmol/mol for paper III + IV. 
4.1 SUBJECT SELECTION 
 Paper I 4.1.1
The abnormalities in the GH-IGF-axis in subjects with type 1 diabetes, which includes 
increased GH secretion during day and night (Halldin, Tylleskar et al. 1998) and subnormal 
IGF-I concentrations are more pronounced in puberty (Acerini, Williams et al. 2001). The 
underlying mechanism responsible for these abnormalities is the lack of hepatic insulin 
actions. Therefore, we hypothesized that improved nightly insulinization achieved with long-
acting analog glargine could be of importance, particularly in puberty. Because of this we 
studied 12 adolescents in pubertal Tanner stages 2 or 3. All subjects and their parents were 
informed and signed informed consent. 
 Paper II 4.1.2
The clinical use of glargine in the pediatric population was established very fast in Sweden. 
Glargine was soon used from the diagnosis of type 1 diabetes. At clinical follow up, the 
effects on HbA1c appeared to be superior compared to treatment with NPH, in accordance 
with results from paper I. Therefore a systematic retrospective study was initiated. Treatment 
effects with glargine were compared to treatment with NPH, both given in a MIT regimen. A 
power calculation showed that 50 patients in each treatment arm were needed to show a 
difference in HbA1c of 1 %-unit. We included the first 49 patients that were treated with 
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glargine from diagnosis and compared with 49 consecutive patients treated close in time with 
NPH. Both groups received the same care and management from the diabetes team. The age 
of the patients included was from 7-17 years. Patients younger than 7 years were not treated 
with glargine at the time, and we wanted to allow the one year follow up to take place at the 
pediatric department before the age of 18 years. The glargine group was diagnosed from 
August 2002 until September 2003. At that time-point the initial patient management 
program changed and no more patients could therefore be included. The NPH group was 
collected between March 2000 and December 2001. All patients remained on the same initial 
treatment during the first year from diagnosis. 
 Paper III+IV 4.1.3
The effects of different insulin regimens on reversing the abnormalities of the GH-IGF-axis 
are assumed to be more pronounced in individuals lacking endogenous insulin production. 
However, the effects of initial treatment from diagnosis has been shown to be of great 
importance for metabolic control later on (Ludvigsson and Bolli 2001). Following the results 
of paper II, we planned a prospective randomized controlled trial from diagnosis of type 1 
diabetes to investigate effects on metabolic control and underlying mechanisms. At that time 
a second long-acting insulin analog, detemir had been approved and it was, besides glargine 
included in the investigation. A power calculation showed that 40 patients in each treatment 
arm were needed to show a difference in HbA1c of 1 %-unit compared with either of the 
long-acting insulin arms. Since metabolic control, endogenous insulin production and 
abnormalities in the GH-IGF-axis are affected by puberty, the subjects were stratified for 
pubertal status and gender. 
120 patients were enrolled from September 2005 until March 2010. Of the 120 patients 
included, 40, 41 and 39 subjects were assigned to NPH, glargine or detemir. Newly 
diagnosed children with type 1 diabetes were enrolled in the study before they received their 
first subcutaneous insulin injection. While receiving intra venous (iv.) insulin infusion (up to 
48 hours), they and their families were informed about the study. Patients were enrolled if 
they were novel to insulin therapy at admission, age ≥7 years and ≤17 years and they and 
their legal guardians had signed the informed consent form. The exclusion criteria were: 
Moderate to severe diabetes ketoacidosis (pH <7.2 and/or standard bicarbonate < 10 mmol/l), 
suspected non-type 1 diabetes, known celiac disease, hypothyroidism (if not well controlled), 
suspected syndrome, any eating disorder, neuropsychiatric diagnosis or cancer. 
A total of 27 subjects were excluded. Celiac disease is, like type 1 diabetes an autoimmune 
disease and the coexistence is approximately 8 %, varying from 3-16% in different studies 
(Cohn, Sofia et al. 2014). All subjects were screened for celiac disease with IgA 
transglutaminase antibodies at diagnosis, but the test result often came after start of 
subcutaneous insulin. Thus we had to inform and include the patients before the test result 
arrived. A total of 8 (7%) subjects had positive IgA transglutaminase antibodies indicating 
preexisting undiagnosed celiac disease and these patients had to be excluded. 17 subjects 
were excluded on their own request, during the study treatment phase, mainly because of fear 
for the test procedures that involved iv.catheters and CGM. This reason was, as expected, a 
little more prevalent among the younger children. 2 subjects were excluded because of 
protocol violence, both because they were non-compliant to the insulin regimen resulting in a 
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deteriorated metabolic control. Finally one subject was excluded due to newly diagnosed 
Asperger´s syndrome during the study. A flow-chart of included and excluded subjects and 
reasons for exclusion is presented in Fig.4. 
 
4.2 RESEARCH DESIGN 
 Research design in Paper I 4.2.1
The main purpose of paper I was to explore and identify potential reversal of abnormalities in 
the GH-IGF-axis induced by glargine in pubertal adolescents. By the time of planning for the 
study glargine was recently approved. Each subject was her/his own control. A randomized 
cross-over study could be planned later on, if we found support for the involvement of the 
GH-IGF-axis in the improvement of metabolic control. 
At inclusion all 12 subjects were treated with NPH in a MIT regimen. Each subject was 
admitted for a 26 hours period at two different occasions First, still treated with NPH and 
then after 6 weeks on glargine. Subjects were also studied with fasting blood samples in the 
morning after 1, 2, 4, 8, and 12 weeks. Subjects were advised to adjust insulin doses, both 
basal and meal insulin, in order to optimize their glycemic control.  
At start of each admission two iv.catheters were applied and blood samples were obtained at 
start and then every 30 minutes from 21:00 until 17:00 the next day. Hormone analysis taken 
 
Fig.4. Included and excluded and reasons for exclusion in paper III+IV. * The reason for 
exclusion is given by number of subjects: Diagnosed with celiac disease /found non-compliant 
/diagnosed with neuropsychiatric disorder /patient´s or family´s request 
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between 00:00 and 07:00 were considered as overnight values. The first dose of glargine was 
given at 18.00 at the end of the first admission. The research design is presented in Fig.5. 
 
 
 
 
 
 
 
 
 
 Research design in Paper II 4.2.2
This was a retrospective observational study from diagnosis of type 1 diabetes comparing the 
use of glargine versus NPH, both as a part of a MIT insulin regimen. From our clinical patient 
database we collected measurements regarding HbA1c, insulin doses and weight, at 
diagnosis, after 3-5 months, 6-8 months, and 12-15 months of diabetes duration. Gain in 
weight was analyzed as difference in body weight (BW) from 1 month after diagnosis until 
final visit of the study. Clinical visits were not always at exact expected time and therefore 
the time-points are given as an interval (e.g. 3-5 months). 
A retrospective, observational study has several limitations and a high risk of confounders. 
We wanted to take advantage of clinical data in this retrospective design before a costly and 
time-consuming RCT was conducted. 
 Research design in Paper III+IV 4.2.3
This was a randomized controlled clinical trial from diagnosis of type 1 diabetes in children 
and adolescents. We wanted to test the hypothesis that long-acting insulin analogs, because of 
their prolonged effect duration and thereby improved nightly insulinization (Heise and Pieber 
2007), improve metabolic control, prolong endogenous insulin production and reverse the 
abnormalities of the GH-IGF-axis. The hypothesis was generated based from the results in 
papers I and II. Since a second long-acting analog, detemir had been approved, it was 
included in the comparison. Randomization was therefore done to three different basal 
insulins, intermediate- acting NPH or either of the two long-acting analogs, glargine or 
detemir.  
Patients were admitted at diagnosis to the diabetes unit at Astrid Lindgren´s children hospital. 
They were initially treated with iv.insulin infusion for up to 48 hours according to our 
standard treatment protocol. Randomization to NPH, glargine or detemir took place before 
the first subcutaneous insulin injection. The randomization process was stratified for gender 
 
Fig.5. A schematic presentation of the research design in Paper I 
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and puberty. It was designed to give equal numbers of subjects in each treatment group. All 
subjects followed the same educational program and were hospitalized for approximately one 
week, and thereafter had close contact and/or daily visits to the hospital for another week. 
Doses at start of subcutaneous insulin injection therapy were calculated based on insulin 
requirements during iv.insulin infusion according to a predefined scheme. Insulin doses were 
optimized according to the Swedish National Guidelines.  
Blood samples were collected before iv.insulin treatment was started (PI= preinsulin), before 
subcutaneous insulin (PS= presubcutaneous) was started, and with fasting in the morning at 
each study visit at 2 weeks, and at 3, 6, 9 and 12 months. A clinical evaluation including 
pubertal staging and auxology was obtained at each visit. 
The mixed meal tolerance test (MMTT) was performed at 2 weeks and at 3, 6 and 12 months 
to evaluate endogenous insulin production. To evaluate glucose variability, subjects used a 
blinded CGM for 3 days at 3, 6 and 12 months. The 24-hour and overnight (00:00-07:00) 
individual means and SD were calculated for the first full 24 hours available. A glucose 
variability index, MAGE, was calculated from the 24-hour CGM glucose data. Time spent at 
a low (≤ 3.9 mmol/l) or at a high (≥ 10.0 mmol/l) glucose was also calculated. Patients were 
advised to report hypoglycemia in diaries that were collected at each visit. The research 
design is presented in Fig.6. 
 
 
Fig.6. Schematic presentation of the research design in Paper III+IV. 
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4.3 METHODS 
 Glycemic control 4.3.1
 HbA1c 4.3.1.1
Since the DCCT study (DCCT 1995) showed a correlation between intensive insulin 
treatment, improvement in HbA1c and reduction in prevalence of long-term complications, 
HbA1c is a parameter of metabolic control that is used as primary endpoint in most clinical 
comparisons of different insulin regimens in type 1 diabetes. 
In paper I the change in HbA1c from start of the study until the 12 weeks endpoint was 
compared. The HbA1c after 6 weeks was also interpreted, although 6 weeks is a short time to 
monitor a difference in HbA1c. In papers II and III the difference in HbA1c between the 
treatment groups after 12 months was the primary end point. HbA1c was also measured with 
3 months interval to find out the time of nadir. 
In Sweden HbA1c was measured by the Mono-S standard until December 2010, while the 
most used standard for HbA1c is the DCCT standard, which is approximately 1 % unit lower 
than Mono-S standard. For reasons of uniformity the standard was in 2011 changed to IFCC 
standard. In paper III conversions were made using the formula: [(10.45 x HbA1c Mono S 
standard %) – 10.62] = HbA1c IFCC mmol/mol, which is the conversion formula stated to be 
used by the Swedish standardization organ, Equalis. This formula differs just slightly from 
the IFCC master equation, but since our central laboratory used the Equalis standard it was 
essential for us to also do so.  
In paper I, all HbA1c samples were collected on filter paper, analyzed at the central 
laboratory and reported as Mono-S standard. In paper II HbA1c was analyzed either with 
DCA 2000 at the outpatient clinic or on filter paper, analyzed on the central laboratory, 
expressed as the Mono-S standard. In paper III all samples were collected on filter paper. 
Values were then reported as IFCC values after conversion. 
 Fasting-glucose 4.3.1.2
Second to HbA1c, fasting-glucose is the most common marker of glycemic control in clinical 
trials of diabetes. When comparing basal insulins with different duration, it is of great 
importance to compare the fasting-glucose. This measurement is also of great importance 
because of the glucose rise in the dawn phenomena (King, Clark et al. 2012). We studied 
adolescents and the fasting-glucose is of importance in regard to the deterioration in glucose 
control seen in pubertal individuals during late night caused by increased GH secretion 
(Dunger 1992). The sample was obtained after an overnight fast as the zero time-point of the 
MMTT. Given that the subjects had to travel to the hospital, it is possible that the glucose 
value may have been raised by the stress as compared to what we would have obtained at 
wake-up.  
 Continuous glucose monitoring (CGM) 4.3.2
In paper III, a blinded CGM system (CGM Medtronic gold®) was applied for three days at 3, 
6 and 12 months. CGM consists of a disposable transcutaneous glucose sensor along with an 
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electronic transmitter/receiver unit (Wolpert 2010). Because the measurement is blinded to 
the patient, the aim was only to register the glucose variability, not to use it for dose 
adjustments. In general the accuracy of CGM values to blood glucose values has been shown 
to be high, except for very low glucose values (Bay, Kristensen et al. 2013). Some children 
considered it painful to have an iv.catheter or the probe for the CGM inserted. Therefore a 
considerable number rejected this examination. In other cases, we experienced technique 
problems with the CGM. Because of this we have a lower number of observations with these 
parameters. 
From the CGM curves we derived different measures of glucose variability. The 24-hour and 
overnight (00:00-07:00) individual means and SD were calculated for the first full 24 hours 
available. A glucose variability index, MAGE, was calculated from the same 24 hours. Time 
spent at a low (≤ 3.9 mmol/L) or at a high (≥ 10.0 mmol/L) glucose was also calculated. The 
index MAGE was described already in 1970 (Service, Molnar et al. 1970) and it is still used 
as a reliable tool for assessing glucose variability (White, Chase et al. 2009; Ferenci, Korner 
et al. 2015). MAGE doesn´t take the actual glucose level into consideration, but instead only 
the glycemic swings, that exceed one SD. To compensate for this lack of information we also 
registered the time spent in low or high glucose. 
 Endogenous insulin production 4.3.3
To evaluate remaining endogenous insulin production in paper III we performed an MMTT. 
MMTT stimulated C-peptide area under the curve (AUC) is regarded as the golden standard 
(Greenbaum, Mandrup-Poulsen et al. 2008) for evaluation of preserved beta cell capacity. 
The MMTT (Ludvigsson, Faresjo et al. 2008) was performed at 2 weeks and at 3, 6 and 12 
months. In brief, a mixed meal drink (Sustacal - Boost®; 6ml/kg) was given after an 
overnight fast (from 24:00), omitting basal and meal insulin in the morning. Blood samples 
for blood glucose and C-peptide were obtained at 0, 30, 60, 90 and 120 minutes. C-peptide 
AUC was calculated using the trapezoidal rule. The AUC mean equals the AUC divided by 
the interval of time, as with 120 minutes for a 2-hour MMTT, for example. 
 Anthropometric measurements and body composition  4.3.4
It is established that the body mass index (BMI) is an index of relative fatness. The measure 
has been validated against body fat measured by DXA in children and adolescents (Lindsay, 
Hanson et al. 2001). In papers I-III the height and weight of all subjects were registered at 
each clinical visit. From this data we calculated the BMI and this value was in paper III 
correlated to the Swedish standard of individuals of the same age and pubertal status to form 
the BMI standard deviation scores (SDS) (Wikland, Luo et al. 2002). In paper III the change 
in BMI from 2 weeks until 12 months was also registered, to consider the change in BMI 
during the study. By doing this this we could compare the influence of the different 
treatments and didn´t have to adjust for group differences at baseline. The reason to compare 
the 12-month value to the value of 2 weeks instead of baseline was that all individuals at 
diagnosis of type 1 diabetes are in varying state of metabolic derangement and hydration and 
often gain several kilos over the first week after rehydration and initiation of insulin therapy. 
By comparing to the 2-week BMI we abolished the effect of this acute weight loss. In the 
retrospective paper II, only weight was registered at every time-point. Therefore no BMI 
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could be calculated and registered variable of body composition was weight gain from 1 
month after diagnosis until end of study at 12-15 months. The rational for comparison to 1 
month weight instead of baseline was the same as in paper III. 
Body fat determinations by bioimpedance have been validated versus DXA, including the 
instrument that we have used (InBody720 2002) and is often easier to perform and does not 
have irradiation effects. In paper III bioimpedance measurements (8-point tactile electrode) 
were performed by InBody 720 (Fysiotest Europa AB, Sweden) to assess the body fat 
percentage (BFP) at each visit. 
In papers I and III the pubertal status was validated by a clinical examination. In paper I all 
individuals were in early or mid-puberty, since pubertal status ≥ 2 was inclusion criteria. In 
paper III+IV pubertal status at baseline was also important for the randomization. The 
pubertal development during the 12-month study was then followed and registered. 
 Insulin doses 4.3.5
Both basal and meal insulin doses per kg were recorded in papers I-III. They may be 
considered a measure of insulin sensitivity. Insulin doses were reported by the subjects at 
each visit and this information tends to not be completely accurate. Subjects may omit dosing 
and still report dosing, which is a strong limitation when comparing insulin doses of different 
insulin regimens, although there is no reason to suspect the misreporting to be different 
between the insulin treatments. 
 GH-IGF-axis 4.3.6
 IGF-I  4.3.6.1
The levels of IGF-I in serum reflects the liver production of IGF-I and are regulated by portal 
insulin through potentiation of the GHR, in numbers and by post receptor effects (Maes, 
Underwood et al. 1986; Hanaire-Broutin, Sallerin-Caute et al. 1996; Hedman, Frystyk et al. 
2004). We assumed that improved insulinization using long-acting insulin analogs should 
have hepatic effects and increased hepatic GH sensitivity leading to increased IGF-I 
production and serum concentration of IGF-I. Therefore, we used serum IGF-I level as an 
indirect marker of hepatic insulin actions in paper I and IV. IGF-I is not directly regulated by 
insulin via GHR signaling: GH status as well IGFBP-3, ALS and other IGFBPs contributes 
by regulating production and serum clearance, respectively. Therefore IGFBP-I, which is 
directly insulin regulated, may be more sensitive, as a marker of hepatic insulin actions, than 
IGF-I. 
In healthy subjects, IGF-I increases in Tanner stage 2-3, reaches a peak in Tanner 3-4 and 
then decreases in late puberty in parallel to the changes in GH secretion (Juul, Bang et al. 
1994). It is therefore important to relate the absolute IGF-I values to pubertal stage and age to 
make the comparison valid. In addition, linear regression analysis is not valid throughout the 
pubertal age range, if IGF-I is not expressed in SD scores. In paper IV, we calculated the sex, 
age and pubertal stage corrected IGF-I SDS by using a formula described previously (Juul, 
Bang et al. 1994). 
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 IGFBP-I 4.3.6.2
Circulating IGFBP-1 is produced almost entirely in the liver and is down-regulated by 
exposure to portal insulin (Brismar, Fernqvist-Forbes et al. 1994). In contrast to endogenous 
insulin, injected insulin reaches the systemic circulation and hepatic insulin levels become 
sub-physiological. IGFBP-1 was shown to be a marker of hepatic insulin sensitivity in 
healthy subjects (Kotronen, Lewitt et al. 2008) and has also been used as a marker of hepatic 
insulin actions in several clinical studies of type 1 diabetes (Hall, Johansson et al. 1989; 
Lepore, Pampanelli et al. 2000). IGFBP-1 was measured in papers I and IV to evaluate portal 
insulin action/ sensitivity. IGFBP-1 is acutely down-regulated by increased hepatic insulin 
levels and has therefore a diurnal variation. Morning levels are high due to overnight fasting 
and are suppressed during the day by insulin release at meals. It is therefore important to 
consider the time-point when IGFBP-1 is measured. In paper I blood samples for IGFBP-1 
were taken every 30 minutes between 21.00 and 17.00 during the two occasions that subjects 
were admitted. The mean values for overnight secretion and total sampling time was 
evaluated. In paper IV only fasting values were obtained. 
 Overnight curves 4.3.6.3
To determine levels of hormones that have a diurnal secretory pattern like GH and IGFBP-1, 
it is necessary to do 24-h or overnight curves. In paper I; GH, IGFBP-1 and IGFBP3-PA were 
analyzed hourly from 21:00 to 17:00 at time-point 0 and at the 6-week admission. 
4.4 BIOCHEMISTRY AND HORMONAL ANALYSIS  
HbA1c- was analyzed on filter paper using high-performance liquid chromatography 
(Variant II; Bio-Rad Laboratories, Hercules, CA, USA) or by DCA 2000 (Bayer, Elkhart, 
USA). The HbA1c assay was monitored against the External Quality Assurance in 
Laboratory Medicine in Sweden reference standard. 
Glucose- was analyzed in whole blood with a bedside glucose dehydrogenase method 
(HemoCue®, Ängelholm, Sweden). 
C-peptide- concentrations in serum samples were determined using a time-resolved 
fluoroimmunoassay (AutoDELFIA™ C-peptide kit, Wallac, Turku, Finland).  
IGF-I- in paper I and IV total serum IGF-I concentrations were determined using an in-house 
des(1-3) IGF-I radioimmunoassay (RIA) after serum extraction by the acid-ethanol method 
followed by cryoprecipitation (Bang, Eriksson et al. 1991). 
IGFBP-1- in paper I the serum IGFBP-1 concentrations were determined by RIA as 
previously described (Pihl, Carlsson-Skwirut et al. 2006), also in paper IV a RIA method was 
used (Povoa, Roovete et al. 1984). 
Serum IGFBP-3 proteolysis (IGFBP-3-PA) - was determined by in vitro degradation of 
125I-IGFBP-3 as previously described (Pihl, Carlsson-Skwirut et al. 2006).  
GH- was analyzed in serum by a commercial dissociation-enhanced lanthanide fluorescence 
immunoassay from Perkin Elmer (Turku, Finland). 
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GHBP- serum GHBP was analyzed with a commercial ELISA (enzyme-linked 
immunoassay) kit (DSL-10-48100; Diagnostic Systems Laboratories). 
All analyses are described in detail in each paper. 
4.5 ETHICS 
In papers I and III+IV all subjects, and their parents, were informed and then gave their 
informed consent. All studies were approved by the Regional Ethical Committee, Stockholm. 
Papers I and III+IV were also approved by the Medical Products Agency, Sweden. For paper 
III+IV the Karolinska Trial Alliance provided monitoring. 
4.6 STATISTICAL ANALYSIS 
All statistical analysis were performed with Sigma Stat 2.0 (Paper I), SAS (Paper II) and 
Sigma Plot 11.0 and SPSS (Papers III and IV). All baseline characteristics are given as 
descriptive characteristics. All follow-up data were tested for normality and expressed as 
mean ± SD (Paper II) or mean ± SE (Papers I, III and IV) if normally distributed, otherwise 
as median (25ͭ ͪ -75ͭ ͪ percentiles). Follow-up data were analyzed using Student´s t-test or 
Rank-Sum test (Paper I-IV), one-way Anova (Papers I, III and IV), one way repeated 
measures Anova (Paper II) and two ways repeated measures Anova (Papers II, III and IV) 
when appropriate. For all pairwise multiple comparison procedures, the Holm-Sidak, or 
Student-Newman-Keuls methods were used. Correlations were analyzed by linear regression 
(Papers I and IV) and by multiple linear regressions (Paper IV). P < 0.05 was considered 
significant. 
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5 RESULTS 
5.1 GLYCEMIC CONTROL 
 HbA1c  5.1.1
In papers I-III HbA1c was lower with long-acting insulin analogs (glargine or detemir) 
compared to NPH at study end point 12 weeks (paper I) or 12 months (papers II and III). 
Paper  NPH Analog (glargine or glargine/detemir) Comparison 
I 8.3 ± 0.6 % (76.1 ± 6.3 mmol/mol) 7.3 ± 0.3 % (65.7 ± 3.2 mmol/mol) 0.008  
II 7.1 ± 1.3 % (63.6 ± 13.6 mmol/mol) 6.3 ± 1.6 % (55.2 ± 16.7mmol/mol) < 0.01 
III (all ages) 6.6 ± 0.2 % (57.9 ± 2.2 mmol/mol) 6.1 ± 0.1 % (52.7 ± 1.0 mmol/mol) 0.019 
III (pubertals) 6.8 ± 0.3 % (60.2 ± 3.2 mmol/mol) 5.9 ± 0.2 % (51.0 ± 1.7 mmol/mol) 0.008 
Table 6: Comparison of HbA1c at end point for papers I-III. Values are given as Mono-S, % and (IFCC, 
mmol/mol) and reported as mean± SE for papers I+III and as mean ± SD for paper II. 
In paper I, treatment with glargine decreased mean ± SE HbA1c from 8.3 ± 0.6% to a nadir 
of 7.3 ± 0.3 % at 6 weeks (P< 0.002). Improvement in HbA1c was significant after 2 weeks 
(7.5 ± 0.4 %, P < 0.008) and was sustained also after12 weeks (7.3± 0.3 %, P< 0.008).  
 
In paper II, HbA1c in the glargine group was lower at all follow up time-points compared to 
NPH (Fig.7). 
 
 
 
 
 
 
 
 
 
Fig.7. HbA1c at diagnosis and follow-up in paper II: at 3-5 months, 
6-8 months, and 12-15 months in patients treated from diagnosis with NPH (open bars) or 
glargine (hatched bars) in an MIT regimen. Results presented as mean ± SD. *p < 0.05, **p < 
0.01, and ***p < 0.001 by two-way repeated measures Anova. 
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In paper III, mean ± SE HbA1c at 12 months 
was lower with analogs compared to NPH 
(52.7 ± 1.0 vs. 57.9 ± 2.2 mmol/mol, P = 
0.019). This difference was entirely due to 
lower HbA1c in pubertal children (51.0 ± 1.7 
vs. 60.2 ± 3.2 mmol/mol, P = 0.008) (Fig.8). 
The 12-month HbA1c differed among the three 
basal insulin treatment groups in pubertal 
children (P = 0.026), but not in prepubertal    
(P = 0.34).In pubertal subjects, HbA1c in 
NPH-treated (60.2 ± 3.2 mmol/mol) was 
borderline higher than glargine (52.3 ± 3.1 
mmol/mol, P = 0.057) and significantly higher 
than detemir (49.8 ± 1.9 mmol/mol, P = 0.01). 
There were no differences between analogs 
and NPH at any other time-point. HbA1c 
decreased rapidly after start (P < 0.001) of insulin therapy and reached a nadir at 3 months in 
all treatment groups (Fig. 2C and 2D in paper III). 
 Fasting-glucose 5.1.2
Fasting-glucose values were only assessed in paper III. At 12 months mean ± SE fasting-
glucose was significantly lower in pubertal subjects on analogs vs. NPH (8.2 ± 0.5 vs. 10.5 ± 
0.9 mmol/l). A difference among the three pubertal groups at 12 months almost reached 
statistical significance. No differences were found at other times. 
 Glucose variability 5.1.3
Different measurements of glucose variability, calculated from CGM data were presented in 
paper III. The 12-month individual 24-hour mean and SD of mean of glucose values, mean 
overnight glucose, % of time spent in hyperglycemia or hypoglycemia and MAGE did not 
differ between NPH and analogs (table 2 of paper III) or among treatment groups. 
5.2 ENDOGENOUS INSULIN PRODUCTION  
In paper III we reported that the median (25ͭ ͪ  - 75ͭ ͪ percentiles) 12-month stimulated C-
peptide AUC did not differ between NPH versus analogs (0.16 (0.12 - 0.33) vs. 0.18 (0.08-
0.52) nmol/lx2h, in prepubertal or 0.42 (0.18 - 0.84) vs. 0.51 (0.22 - 0.71) nmol/lx2h, in 
pubertal subjects). 12-month fasting C-peptide did not differ between NPH and analogs (0.35 
(0.18 - 0.47) vs. 0.30 (0.11 - 0.77) nmol/l, in prepubertal or (0.41 (0.21 - 0.98) vs. 0.64 (0.31 -
1.00) nmol/l pubertal subjects. Stimulated C-peptide AUC peaked at 3 months and then 
declined gradually until 12 months (P< 0.001) (Fig.9). The change in stimulated C-peptide 
AUC between 3 and 12 months was not different between NPH and analogs (Table 2 in paper 
III). 
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Fig.8. Hba1c at 12 months in pubertal subjects treated 
from diagnosis with NPH or analogs (glargine or 
detemir). 
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In paper IV we reported that C-peptide AUC predicted HbA1c at 6 and 12 months (r = 0.32, 
P = 0.002 and r = 0.30, P = 0.003, respectively). In a multivariate analysis, insulin group and 
C-peptide AUC at 12-months predicted 39 % of the variation in HbA1c with a contribution 
from both group (P = 0.018) and C-peptide AUC (P = 0.003). At 6 months only C-peptide 
AUC predicted HbA1c (P = 0.002).  
5.3 ANTHROPOMETRIC MEASUREMENTS AND BODY COMPOSITION 
In paper I mean ± SE body weight increased from 46.8 ± 2.5 kg to 48.3 ± 2.5 kg (P = 0.002), 
height from 157.8 ± 2.0 cm to 158.7 ± 2.0 cm (P = 0.002) and BMI from 18.7 ± 0.8 kg/m² to 
19.1 ± 0.9 kg/m² (P = 0.03) from 0 to 6 weeks. 
In paper II mean ± SD weight gain did not differ between groups; 5.69 ± 4.4kg in the NPH-
group vs.5.69 ± 4.1 kg with glargine. 
In paper III, no differences in 12-month BMI SDS, change in BMI SDS from 2 weeks to 12 
months, 12-month BFP, or change in BFP from 2 weeks to 12 months were observed 
between NPH and analogs or among the treatment groups. Values are reported in table 2, 
paper III.  
5.4 INSULIN DOSES 
In paper I, the mean ± SE total daily insulin dose at first evaluation was 1.21 ± 0.12 IU/ kg, 
and after 6 weeks, 1.05± 0.11 IU /kg or 89 ± 6% of the initial dose (P = ns). However, the 
change of total insulin dose and in IGF-I was positively correlated (r = 0.61, P = 0.046). 
In paper II, the mean ± SD total insulin dose (basal and meal) was similar at nadir (lowest 
point), 0.47 ± 0.16 U/kg with glargine vs. 0.51 ± 0.20 U/kg with NPH. At 12-15 months the 
dose was lower with glargine vs. NPH (0.64 ± 0.23 vs. 0.86 ± 0.31 U/kg; P < 0.001). 
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Fig.9. C-peptide AUC in A. prepubertal and B. pubertal subjects from diagnosis treated with NPH (solid 
line), glargine (dashed lines) and detemir (dashed and dotted lines). * P < 0.001 from all other time-
points. 
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In paper III, the lowest basal and meal insulin doses were seen at 3 months, with no 
difference among the treatment groups. At 12 months, mean basal doses had increased 
approximately 30 % in NPH and glargine, and almost 50 % in detemir. The detemir dose was 
0.47 units/kg, 67 % higher compared to glargine (0.28 U/kg, P < 0.001) and 27 % higher than 
NPH (0.37 U/kg, P < 0.022) for all subjects. The 12-month basal insulin requirements were 
approximately 30 % higher in pubertal children compared to prepubertal. The 12-month meal 
doses did not differ among the groups. 
5.5 GH-IGF-AXIS 
 IGF-I 5.5.1
In paper I, the mean ± SE IGF-I level increased, from 231 ± 19 at time-point zero to 309 ± 
17 µg/l after 1 week (P < 0.001). At the 6 weeks admission, IGF-I was 274 ± 25 µg/l (P = 
0.022). It peaked at 12 months, 347 ± 25 µg/l (P < 0.001), 54 ± 9% over baseline. HbA1c at 
time-point zero was positively correlated with the increase of IGF-I at all time-points (r = 
0.93, P < 0.001 at 6 weeks). The change in HbA1c over time mirrored that of IGF-I (Fig 1 in 
paper I). 
 
The individual IGF-I SDS of all subjects in paper I is shown in Fig.10. The mean ± SE IGF-
SDS was subnormal on NPH at time-point zero (-1.8 ± 0.4). Although, at 12 weeks mean 
IGF-I SDS had increased to -0.55 ± 0.3 SDS (P < 0.001). 
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Fig.10. Changes in individual IGF-I SDS during 12 weeks of glargine treatment in adolescents with 
type 1 diabetes, earlier treated with NPH. 
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In paper IV the 12-month mean IGF-I SDS did not differ among the three insulin groups or 
between NPH and analogs in prepubertal or pubertal subjects. Neither were there any 
differences at 3 and 6 months, respectively (Table 2, paper IV). IGF-I SDS changed over 
time, with the lowest values at PI and PS in both prepubertal and pubertal subjects. IGF-I 
SDS increased towards normal levels at 2 weeks in all treatment groups. In pubertal subjects, 
IGF-I SDS then declined to markedly subnormal levels at 12 months while the prepubertal 
IGF-I SDS levels were less subnormal (Fig.11). 
 
Fig.11. IGF-I SDS over time in A. prepubertal and B. pubertal subjects treated with NPH (solid line), glargine 
(dashed line) and detemir (dashed-dotted line) from diagnosis of type 1 diabetes. 
* Difference for all subjects at that time-point compared to all other time-points, P< 0.001† Difference for all 
subjects at that time-point compared to 2 weeks, P= 0.006. § Difference for all subjects at that time-point 
compared to 2 weeks, P < 0.001.  
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Fig.12. IGF-I SDS at 12 months was inversely correlated with C-peptide AUC at 12 months 
in all subjects treated with NPH, glargine or detemir from diagnosis of type 1 diabetes. 
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In paper IV univariate analysis demonstrated that 12-month IGF-I SDS was inversely 
dependent on C-peptide AUC (r = -0.23, P = 0.029) (Fig.12 on p. 33). The 6-month IGF-I 
SDS did not correlate with C-peptide AUC. However, 12-month IGF-I SDS was strongly 
inversely dependent on age (r = -0.47, P < 0.001) and tanner stage (r = -0.56, P < 0.001) and 
in multivariate analysis the dependency on C-peptide was lost. 
To summarize, we found an increase in IGF-I SDS in paper I, when changing from NPH to 
glargine. This difference in IGF-I SDS could not be seen when comparing NPH to glargine or 
detemir from diagnosis in paper IV; however, there was an increase in IGF-I SDS in all 
treatment groups, with a maximum level at 2 weeks. In both paper I and IV all individuals 
and especially those in puberty had subnormal IGF-I SDS levels. 
 
 IGFBP-1 5.5.2
In paper I, individual IGFBP-1 
patterns increased at late night and 
early morning. On glargine the 
morning values were in some 
individuals lower than on NPH (Fig. 
2A in Paper I).The mean ± SE 
overnight IGFBP-1concentration 
decreased from 127 ± 21 µg/l to 90 ± 
12 µg/l at 6 weeks (P = 0.035) 
(Fig.13), but was not significantly 
lower with glargine when evaluated 
over the total 20 hours admission 
period (P = 0.065). 
 
 
 
In paper IV, the 12-month mean ± SE IGFBP-1 was lower in pubertal subjects on analogs 
than on NPH (69.4 ± 6.9 vs. 98.7 ± 13.9 µg/l, P = 0.04) (Table 2, paper IV). No difference in 
IGFBP-1 was found among pubertal subjects on NPH (98.7 ± 14 µg/l), glargine (69.5 ± 9 
µg/l) or detemir (69.2 ± 12 µg/l), P = 0.12 at 12 months with one way Anova. IGFBP-1 was 
also lower in pubertal subjects on analogs than on NPH at 3 and 6 months (Table 2, paper 
IV). In the prepubertal subjects, no difference was found between NPH and analogs at any 
time-point (Table 2, paper IV). 
 
Fig.13. IGFBP-1 mean overnight concentration (00.00-
10.00) on NPH (baseline) and after 6 weeks with glargine 
in adolescents with typ1 diabetes. 
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IGFBP-1 was at its lowest level at PS in both prepubertal and pubertal subjects (Fig.14). With 
repeated measures Anova at 6 and 12 months in pubertal subjects both glargine and detemir 
were lower than NPH, but significantly only with detemir (Fig.14).In prepubertal subjects 
IGFBP-1 was lower in glargine compared to detemir by repeated measures Anova at 6 
months. Prepubertal values were higher than pubertal at all time-points. 
 
Univariate analysis demonstrated that 6- and 12-month (Fig.15) IGFBP-1 were inversely 
dependent on C-peptide AUC (r = -0.47, P < 0.001 and r = -0.28, P = 0.007). The 6- and 12-
month IGFBP-1 was also strongly dependent on age (r = -0.55, P < 0.001 and r = -0.56, P 
<0.001, respectively) and tanner stage (r = -0.57, P < 0.001 and r = -0.58, P < 0.001, 
respectively). In multivariate analysis these parameters predicted 63 % of the variation in 6 
months IGFBP-1 with C-peptide as the strongest predictor (P= 0.002), while C-peptide did 
not contribute to IGFBP-1 prediction at 12 months. 
 
Fig.14. IGFBP-1 over time in A. prepubertal and B. pubertal subjects treated from diagnosis with 
NPH (solid line), glargine (dashed line) and detemir (dashed-dotted line). 
* Difference for all subjects at that time-point compared to all other time-points, P< 0.001. 
†Difference between subjects treated with glargine and detemir at that time-point by repeated 
measures Anova, P= 0.046. § Difference between subjects treated with NPH and detemir at that 
time-point by repeated measures Anova, P= 0.03. 
IG
F
B
P
-1
 (

g
/l
)
0
50
100
150
200
0
50
100
150
200
PI
PS
3 m6 m 12 m2 w
*
†
A.
§
PI
PS
2 w3 m 6 m12 m
Time-points
B.
C-peptide (nmol/lx2h)
0,0 0,2 0,4 0,6 0,8 1,0 1,2 1,4
IG
F
B
P
-1
 (

g
l
)
0
50
100
150
200
250
 
Fig.15. 12-month IGFBP-1 correlated inversely with 12-month C-peptide AUC in all 
subjects treated with NPH, glargine or detemir from diagnosis (r = -0.28, P = 0.007). 
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To summarize; lower IGFBP-1 by treatment with analogs, glargine or detemir, were shown in 
pubertal subjects in both papers I and IV. 
 GH, GHBP and IGFBP3-PA 5.5.3
GH, GHBP and IGFBP3-PA were investigated during the two admissions at 0 and 6 weeks in 
paper I. The individual GH patterns did not differ between treatment with NPH (0 weeks) or 
glargine (6 weeks) (Fig.2B in paper I). The mean ± SE GHBP did not did not differ between 
time-point zero and 6 weeks (523± 95 vs. 488± 80 pmol/l). The mean IGFBP3-PA was lower 
with glargine (P< 0.001). The mean values of IGFBP3-PA during day time were higher than 
values during night with both NPH and glargine. 
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6 GENERAL DISCUSSION 
Long-acting insulin analogs, glargine and detemir, have a prolonged and more reproducible 
insulin profile compared with the intermediate-acting NPH (Heise and Pieber 2007). The 
overall hypothesis for this thesis is that treatment with long-acting insulin analogs, glargine or 
detemir, in children and adolescents with type 1 diabetes results in better metabolic control, 
increased endogenous insulin production, and normalization of the GH-IGF-axis. The four 
papers all address these questions in different study settings. 
6.1 METABOLIC CONTROL 
In paper I we found a 1 % unit (10 mmol/mol) lower HbA1c in 12 adolescents with type 1 
diabetes, 12 weeks after changing from NPH to glargine. The same has been shown in other 
observational, non-randomized studies, both in adults (Manini, Forlani et al. 2007) and in 
children and adolescents (Chase, Dixon et al. 2003; Hathout, Fujishige et al. 2003; Jackson, 
Ternand et al. 2003; Alemzadeh, Berhe et al. 2005; Colino, Lopez-Capape et al. 2005; 
Urakami, Naito et al. 2014). One non-randomized study, over 12 months failed to show a 
difference in HbA1c (Paivarinta, Tapanainen et al. 2008), while one early randomized study 
showed equal HbA1c, but an improvement in fasting-glucose (Raskin, Klaff et al. 2000). 
Paper I explored the potential effects of long-acting analogs on the GH-IGF-system. The 
study was not designed to make final conclusions regarding the effects on HbA1c, since it 
lacks a control group. When changing from one treatment to another in a study environment, 
subjects are encouraged to perform better and the tight follow up and increased supervision 
can therefore lead to better compliance and thereby an improved HbA1c (placebo effect). 
This confounder is also discussed by Jackson et al (Jackson, Ternand et al. 2003) in their 
study of children and adolescents with type 1 diabetes. A subgroup with poor metabolic 
control had greater improvement in HbA1c and they discussed whether the reason was that 
this group benefitted more from increased supervision. We also observed a BMI gain during 
the study, although, glargine is not reported to induce weight gain (Monami, Marchionni et 
al. 2009). Poor baseline metabolic control with a mean HbA1c of 8% (73 mmol/mol) in our 
subjects may be more likely to cause a BMI increase when glycemia is improved. 
In paper II we showed lower HbA1c after one year in children with type 1 diabetes treated 
from diagnosis with glargine or NPH, in a retrospective study. Studying metabolic control 
from diagnosis, in patients with a significant remaining endogenous insulin production, is 
different from studies performed on subjects with more than one year of duration of diabetes. 
Few studies on type 1 diabetes are performed from diagnosis. Adhikari et al. also showed 
lower HbA1c 1 year from diagnosis, but they retrospectively compared glargine, once daily 
in a MIT regimen versus conventional therapy with NPH twice daily (Adhikari, Adams-Huet 
et al. 2009). Intensive insulin treatment including MIT or CSII (DCCT 1993) and also an 
increased number of boluses (Danne, Battelino et al. 2008) are shown to improve metabolic 
control. Therefore the improvement reported by Adhikari et al. may not be entirely due to the 
treatment with glargine, but could have a significant contribution from the intensified 
treatment by a MIT regimen. In another study, starting close to diagnosis, Hassan et al. 
showed better HbA1c with glargine compared to NPH (Hassan, Rodriguez et al. 2008). Here 
identical regimens were used. They randomized to either glargine or NPH, both basal insulins 
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given twice daily at the same time as the two daily injections of rapid-acting analog. Thus, 
none of these regimens can be expected to be optimal or realistic in an up-to-date clinical 
setting. Glargine is likely to require a MIT regimen to be advantageous, since it does not 
provide meal coverage for the next meal. In contrast, NPH has a significant effect peak 4-6 
hours after injection which may cover lunch after a pre-breakfast injection and a snack in the 
evening after the pre-dinner injection. Therefore, the advantage of glargine reported by 
Hassan et al is somewhat surprising. With the prolonged action of glargine, compared to 
NPH, the insulin action profile will be more physiological with glargine given in a MIT 
regimen.(Hirsch 2005; Porcellati, Bolli et al. 2011). 
In paper III, we compared long-acting analogs, glargine or detemir versus NPH in a RCT 
from diagnosis of type 1 diabetes. The primary end point was HbA1c after 12 months. We 
found lower HbA1c with the analogs compared to NPH. By stratifying patients for pubertal 
status, we were able to show that the advantage of glargine and detemir was only found in the 
pubertal subjects. This is the first study to show lower HbA1c in children in a RCT and this is 
the first study to assess the effects of long-acting insulin analogs from diagnosis over 12 
months. Other RCTs in adults have also showed lower HbA1c with glargine (Porcellati, 
Rossetti et al. 2004; Fulcher, Gilbert et al. 2005; Chatterjee, Jarvis-Kay et al. 2007) or detemir 
(Home, Bartley et al. 2004), but in children and adolescents all RCTs over more than 3 
months have failed to show an advantage of long-acting insulin analogs on HbA1c (Schober, 
Schoenle et al. 2002; Murphy, Keane et al. 2003; Robertson, Schoenle et al. 2007; Chase, 
Arslanian et al. 2008; Thalange, Bereket et al. 2011; Thalange, Bereket et al. 2013; Rostami, 
Setoodeh et al. 2014). Chase et al (Chase, Arslanian et al. 2008) showed lower HbA1c after 6 
months, with glargine compared to NPH, in a subgroup of adolescents that had the highest 
HbA1c. It is possible that this subgroup consisted of a majority of pubertal patients, in whom 
suboptimal control and a greater degree of insulin resistance are common and that they 
benefited more from improved insulinization by glargine. Another possible reason for the 
improvement is that those with poor metabolic control received more benefit from the 
regulated study conditions and increased guidance, than those with good metabolic control, 
who may have already had more regulated control of their diabetes previous to the study. 
In paper III we stratified for puberty and the improvement in HbA1c was only seen in the 
pubertal subjects treated with glargine or detemir. It is well known that insulin resistance 
during puberty is further augmented in adolescents with type 1 diabetes, mainly as a result of 
insufficient portal insulin exposure and consequently low IGF-I and hyper-secretion of GH 
(Dunger 1992; Acerini, Williams et al. 2001). The increase in insulin requirements, 
particularly during the early morning, should be favored by the pharmacokinetic profiles of 
glargine or detemir with sustained insulin effects. In contrast to our study, few other studies 
have stratified for puberty. Contrary to our findings, a Japanese survey saw less significant 
improvement in HbA1c with glargine in the older age group compared to those below 13 
years of age (Urakami, Naito et al. 2014). Thalange et al. also subdivided their study 
population according to age, but the HbA1c didn´t differ in any age group in the comparison 
of detemir and NPH (Thalange, Bereket et al. 2013). 
The use of CSII, like long-acting analogs, is a more physiological way to deliver insulin 
(Bolli, Andreoli et al. 2011) that has been compared to NPH or long-acting analogs with MIT 
in two meta-analysis in children. A small beneficial effect on HbA1c with CSII has been 
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found in both (Churchill, Ruppe et al. 2009; Pankowska, Blazik et al. 2009). None of the 
included studies assessed patients from diagnosis. A Swedish study compared CSII to NPH 
with MIT from diagnosis of type 1 diabetes in children and adolescents. They could not show 
improved HbA1c with CSII (Skogsberg, Fors et al. 2008). They studied a similar age group 
to our study, although they did not stratify for puberty, which may have prevented them from 
finding a small benefit of CSII in the pubertal group. The recently introduced ultra-long-
acting insulin analog, degludec (Biester, Blaesig et al. 2014) can be expected to have a 
positive effect on metabolic control. However a meta-analysis has showed no beneficial 
effect on metabolic control compared to glargine and detemir (Dzygalo, Golicki et al. 2014). 
Additionally an RCT, comparing degludec to detemir in children over 26 weeks, also showed 
comparable HbA1c (Thalange, Deeb et al. 2015). 
Fasting-glucose is an important measure of glycemic control complementing HbA1c, and it 
may more specifically reflect the impact of the nighttime insulin effects of basal insulin in 
patients with type 1 diabetes. Fasting-glucose was measured in paper III and like HbA1c it 
was lower in pubertal subjects treated with long-acting analogs. Several RCTs in adults 
showed both better HbA1c and lower fasting-glucose (Home, Bartley et al. 2004; Porcellati, 
Rossetti et al. 2004; Fulcher, Gilbert et al. 2005; Chatterjee, Jarvis-Kay et al. 2007). In 
children, the only study to show concomitant improvements in HbA1c and fasting-glucose 
was the study by Hassan et al.(Hassan, Rodriguez et al. 2008), where they investigated 
children close to diagnosis, but their study design had limitations as already discussed above. 
There are several studies, both in adults and children that failed to show better HbA1c. 
However, several of these studies reported lower fasting-glucose with glargine or detemir 
(Ratner, Hirsch et al. 2000; Schober, Schoenle et al. 2002; Murphy, Keane et al. 2003; 
Russell-Jones, Simpson et al. 2004; Robertson, Schoenle et al. 2007) compared to NPH. One 
reason for finding improved fasting-glucose, but not better overall improved glycemia 
leading to better HbA1c could be that the long-acting analogs have larger impact on 
nighttime insulin delivery. 
A unique part of our study was to provide repeated three day CGM measurements during the 
study. However, the CGM measurements did not support that overnight glycemia or glucose 
variability calculated as SD of mean glucose or MAGE were improved. Moreover, the 24-
hour data did not support the improvement in HbA1c that we found in the pubertal subjects. 
One possible explanation for this is that loss of data from children who rejected carrying the 
CGM affected our chance to detect differences. Our results accorded with a study in adults 
treated with glargine compared to NPH over 36 weeks, reporting lower HbA1c and lower 
fasting-glucose, but no difference in glucose by CGM (Chatterjee, Jarvis-Kay et al. 2007). 
In this study, the number of subjects that had the CGM was as in our study low. A subgroup 
of pubertal children with type 1 diabetes included in a RCT comparing glargine and NPH 
(Chase, Arslanian et al. 2008) were investigated with CGM and, in contrast to our study, 
White et al. showed lower glucose variability and no difference in HbA1c (White, Chase et 
al. 2009). Similar to our study they assessed MAGE and SD of glucose, among other glucose 
variability indexes. In contrast to our study population, these adolescents were C-peptide 
negative and had fairly poor metabolic control, which makes a comparison to our findings 
difficult. In conclusion, not only HbA1c, but also glucose variability is believed to be 
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important to delay vascular complications (Monnier, Colette et al. 2010) and should therefore 
also be taken into consideration when evaluating the metabolic control of a patient. 
We found no differences in time spent with high (> 10 mmol/l) or low (< 3.5 mmol/l) blood 
glucose over 24 hours. Neither were there any differences in overnight (00 - 07) mean 
glucose. In contrast, the meta-analysis by Monami reported significantly less nocturnal 
hypoglycemia with long-acting analogs (Monami, Marchionni et al. 2009). A 16-week 
crossover study with NPH versus glargine in adolescents, performing overnight glucose 
profiles, reported lower overnight mean with NPH, meanwhile lower fasting-glucose and 
less nocturnal hypoglycemia with glargine (Murphy, Keane et al. 2003). Most likely these 
apparently contrasting results are explained by the insulin profile of NPH, with a prominent 
peak around midnight, causing hypoglycemia and later failure to provide adequate 
insulinization at dawn, resulting in higher fasting-glucose with NPH. 
6.2 ENDOGENOUS INSULIN PRODUCTION AND INSULIN DOSES 
Intensive insulin treatment from diagnosis of type 1 diabetes induces beta cell rest and may 
thereby prolong and enhance endogenous insulin production (DCCT 1998). The capacity of 
an individual to secrete endogenous insulin can be measured by quantification of the secreted 
amount of C-peptide after a mixed meal, a MMTT. Furthermore, preserved endogenous 
insulin can be supposed to decrease the need for exogenous insulin. However, to use the need 
of exogenous insulin to assess endogenous insulin production has several limitations, even if 
the subject has adequate metabolic control.  
In paper I we assessed pubertal individuals with diabetes duration of one to six years, but did 
not measure endogenous insulin production. Preserved beta cells capacity is higher during the 
first year from diagnosis and can be found as long as up to five year from diagnosis in some 
individuals (Steele, Hagopian et al. 2004; Greenbaum, Anderson et al. 2009). Given this it is 
possible that some of the individuals in paper I had remaining endogenous insulin. It is, 
however, unlikely that major changes in C-peptide should occur during the 12 weeks of that 
study or that such changes would impact on HbA1c or the GH-IGF-axis, particularly given 
the C-peptide results from paper III discussed below. 
In paper II we retrospectively compared children with newly diagnosed type 1 diabetes 
treated with NPH or glargine, through obtaining clinical data from patient’s electronic 
records. Fasting C-peptide was not routinely measured and therefore could not be 
investigated. The two groups were comparable in all aspects except from basal insulin 
treatment. We found that the glargine treated group, not only had lower HbA1c, but also 
reported lower insulin doses at 12 months from diagnosis. Using exogenous insulin 
requirements as a proxy for endogenous insulin production, we hypothesized that the lower 
insulin need could be due to better preserved endogenous insulin production and that this was 
one factor that explained improved HbA1c in the glargine treated group. To investigate this 
further we performed a MMTT at 4 different time-points in paper III. We found no evidence 
of higher C-peptide AUC at 12 months, or a slower decrease from baseline in children on 
analogs versus NPH. These findings did not support our hypothesis that improved metabolic 
control was related to better preserved beta cell capacity. On the other hand, in paper IV we 
report that 6- and 12-month C-peptide AUC predicted HbA1c in a univariate analysis, and in 
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multivariate analysis we found that both insulin treatment group and C-peptide AUC were 
important for 12-month HbA1c. In contrast, only C-peptide AUC predicted 6-month HbA1c, 
which may suggest a role of endogenous insulin production on metabolic control at least on 
an individual level. Endogenous insulin is often well-preserved during the first year with type 
1 diabetes in children (Greenbaum, Anderson et al. 2009). Therefore it is possible that an 
effect of the analogs on C-peptide on a group level would become apparent later on. In this 
aspect, the follow up time of only one year, is a limitation. Furthermore, newly diagnosed 
children may benefit from their endogenous insulin secretion, and may therefore not be so 
dependent on exogenous insulin. However, this did not prevent us from demonstrating an 
effect of analogs on HbA1c in the pubertal children.  
We found the maximum stimulated C-peptide levels to occur after 3 months and then noticed 
a small decline until 12 months. At 12 months most individuals had levels of C-peptide > 0.2 
nmol/l, which is the commonly used cut-off for C-peptide positivity These findings accorded 
with previous studies, showing that most children and adolescents have the capacity to 
secrete C-peptide 1 year from diagnosis (Greenbaum, Anderson et al. 2009). In paper III, C-
peptide levels were higher in pubertal subjects versus prepubertal. This might be explained by 
a faster decline in C-peptide levels in younger children (Greenbaum, Beam et al. 2012), but is 
in opposition to our finding that the decline in C-peptide from 3 until 12 months did not differ 
between prepubertal and pubertal subjects. 
Beta cell capacity was evaluated by a 2 hours MMTT, at fasting conditions in the morning 
(Ludvigsson, Faresjo et al. 2008). All individuals took their basal insulin in the evening prior 
to the test, but they did not take basal insulin (or meal insulin) the morning of the test. 
Whether a more sustained insulin effect of the analogs during the night may have affected the 
stimulated insulin/C-peptide release during the MMTT is not known. An increased release is 
possible if endogenous insulin release is spared by a sustained effect of analogs. However, it 
may also be speculated that a decreased release could be observed, if exogenous insulin 
covers part of the insulin need in patients with euglycemia during the test. Against findings 
that the nightly action of the basal insulin would affect the c-peptide concentration, Besser et 
al. found that by giving insulin during a MMTT, the C-peptide is only slightly reduced 
(Besser, Jones et al. 2012). 
Long-acting insulin analogs given in a MIT regimen with rapid-acting meal insulin is thought 
to provide a more physiological insulin profile. This may also be achieved by the use of CSII 
(Bolli, Andreoli et al. 2011). Our research group has recently found that treatment with CSII 
versus NPH in a MIT regimen from diagnosis of type 1 diabetes did not increase endogenous 
insulin secretion in children and adolescents (Ekström, Skogsberg et al. 2013). In an older 
study, comparing CSII to conventional therapy from diagnosis, de Beaufort et al. reported 
better HbA1c after 2 years, but no difference in glucagon stimulated C-peptide or urinary C-
peptide. They argued that the reason there was not better preservation of C-peptide with CSII 
was the young age of the patients, < 15 years, according to the inverse relation between loss 
of C-peptide and age (de Beaufort, Houtzagers et al. 1989). Furthermore, in a more recent 
study, which compared treatment with CSII to glargine in adolescents with newly diagnosed 
diabetes at 12 months, Thrailkill et al. found improved HbA1c (Thrailkill, Moreau et al. 
2011), but failed to show significantly higher stimulated C-peptide levels with CSII. A 
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difficulty comparing C-peptide levels among studies are the heterogeneity of C-peptide 
assays used. 
The exogenous insulin dose needed to lower glucose to a desired level is dependent on 
endogenous insulin secreting capacity, insulin sensitivity and how and where the insulin is 
administrated (Wiegand, Raile et al. 2008). In paper III we evaluated the basal insulin dose 
and found no difference between glargine and NPH treated subjects after 12 months. This is 
in opposition to our finding in paper II of lower doses with glargine treatment after one year. 
In paper III the doses of detemir at 12 months were 67 % higher than those of glargine (P < 
0.001) and 27% higher than those of NPH (P < 0.022). One reason for the higher detemir 
doses could be the bi-daily delivery, although NPH was also given bi-daily. This dose 
relation between glargine and detemir is according to what Porcellati et al. found in a clamp 
study, directly comparing glargine and detemir, where one unit of detemir was 30% less 
active than 1 unit of glargine, estimated by the need of iv glucose (Porcellati, Rossetti et al. 
2007). In vitro data indicates that detemir has a lower affinity to the IR and therefore has a 4-
fold lower metabolic effect than human insulin (Kurtzhals, Schaffer et al. 2000). When 
detemir was developed in clinical trials, it was assigned a lower insulin units/mole than the 
other insulin analogs (which means that more moles of detemir are given for the same 
number of units of insulin). However, it seems that this potency assignment was not exact. A 
retrospective comparison in children showed 27 % higher basal insulin doses with detemir 
compared to glargine, but no other differences between the groups except that a higher 
proportion with detemir were treated twice daily (Abali, Turan et al. 2014). As a proxy for 
insulin sensitivity or endogenous insulin production, comparisons of total daily insulin needs 
in a detemir regimen compared to other basal insulin regimens is not going to be meaningful. 
In paper III the reported insulin doses reached a nadir in all treatment groups at 3 months 
and thereafter doses increased. At 12 months mean basal doses had increased 
approximately 30 % in NPH and glargine, and almost 50 % in detemir. The time-point for 
the nadir coincides with the time for the maximal C-peptide levels. This finding speaks in 
favor of an effect of endogenous insulin secretion on reducing the need of exogenous 
insulin. 
6.3 BODY COMPOSITION 
Both in vitro (Kurtzhals, Schaffer et al. 2000) and in vivo clamp studies (Porcellati, Rossetti 
et al. 2007) show that detemir has a lower lipogenic effect than human insulin and glargine. 
This could explain why treatment with detemir is associated with less weight gain in most 
RCTs (Monami, Marchionni et al. 2009). We examined both BMI gain and increased BFP in 
paper III. In contrast to other studies in children and adolescents (Robertson, Schoenle et al. 
2007; Thalange, Bereket et al. 2013), we found no differences between the insulin treatments 
in any of these aspects. It should be taken into consideration that detemir was given in a 
larger dose in our study and resulted in better HbA1c. If improvements in HbA1c are not 
achieved, less effect on weight gain may be expected. In the referred studies, no differences 
in doses were reported and both NPH and detemir were used either once or twice daily. It has 
been speculated that both free and albumin-bound detemir can pass into the liver, while only 
free detemir can pass over the capillary wall. This could possibly result in a greater effect of 
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detemir on the liver than on peripheral tissue and thereby contribute to why detemir is seen to 
lead to lesser weight gain (Hordern, Wright et al. 2005). 
In paper II we found no differences in weight gain between glargine and NPH, despite the 
improvement in metabolic control. Meanwhile in paper I we found an increase in weight with 
the use of glargine and regarded the improvement of glycemic levels as an explanation for 
this (discussed in chapter 6.1). 
6.4 GH-IGF-AXIS 
Long-acting insulin analogs, glargine and detemir both have an extended duration (Heise and 
Pieber 2007) which implies that they may provide improved nightly insulinization. We 
therefore hypothesized that these insulins could increase IGF-I and decrease IGFBP-1 serum 
concentrations, in pubertal subjects with type 1 diabetes. We tested this hypothesis in papers I 
and IV. 
 
In paper I we found a 50 % increase in IGF-I in the pubertal subjects after changing to 
glargine, and this may have contributed to the improved metabolic control. However, despite 
lower HbA1c with long-acting analogs in pubertal subjects in paper IV, we did not find 
higher IGF-I SDS in these individuals. While insulin is the main regulator of IGFBP-1 
(Brismar, Fernqvist-Forbes et al. 1994), total circulating levels of IGF-I are also dependent on 
GH status as well as on IGFBP-3, ALS and other IGFBPs. Furthermore, circulating IGF-I 
levels are shown to be affected by increased IGFBP-3 proteolysis in pubertal subjects with 
type 1 diabetes (Zachrisson, Brismar et al. 2000). 
IGF-I levels in untreated type 1 diabetes are very low due to severe insulin deficiency and are 
further affected by severely increased insulin resistance, resulting from the catabolic status of 
untreated type 1 diabetes. In paper IV we found very low IGF-I SDS values in the newly 
diagnosed children. The mean IGF-I SDS values in the prepubertal individuals were -2 and in 
the pubertal individuals even lower, at -3. This is in accordance with previous studies 
 
Fig.16. Schematic presentation of the hypothesis of this thesis, that long-acting insulin analogs could 
provide sustained insulin actions during late night could and normalize changes in GH-IGF-axis .with 
the use of long-acting insulin analogs. 
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(Bereket, Lang et al. 1995; Shiva, Behbod et al. 2013).The IGF-I SDS levels increased 
already by the first iv.infusion of insulin and reached its maximum at 2 weeks, although the 
levels were not normalized. As expected and in line with a previous report from our group 
(Zachrisson, Brismar et al. 1997), the levels were even more subnormal in the pubertal age 
group. Surprisingly, even though well treated children have fairly high levels of endogenous 
insulin production during the first year, as reported in paper III and by others from diagnosis 
(Greenbaum, Anderson et al. 2009), we demonstrated that they still have IGF-I SDS below 
zero. Few studies have reported IGF-I SDS, but our findings are in line with a report by 
Strasser-Vogel et al. (Strasser-Vogel, Blum et al. 1995). In paper I the 12 pubertal subjects 
had a mean IGF-I SDS of about -2 on NPH and increased after 12 weeks on glargine to -1, 
still far below the normal mean. We found no suppression of GH secretion at 6 weeks, which 
suggests that IGF-I might need to reach a completely normal level before inhibiting GH. In 
line with this Saukkonen et al. found, in a study with combined rhIGF-I and rhIGFBP-3 
treatment, that almost a 100% increase in serum IGF-I was needed to decrease GH 
(Saukkonen, Amin et al. 2004). IGF-I signaling is involved in the development of vascular 
complications caused by hyperglycemia (Clemmons, Maile et al. 2011), and cardiovascular 
disease risk factors are inversely related to insulin sensitivity in adolescents with type 1 
diabetes (Specht, Wadwa et al. 2013). Therefore it is important that from the beginning of the 
disease to retrieve normalization of the GH-IGF-I system and thereby increasing insulin 
sensitivity. 
Treatment with rhIGF-I has been shown to have effects that increase glucose uptake and 
insulin sensitivity, and improve metabolic control in type 1 diabetes (Acerini and Dunger 
2000; O'Connell and Clemmons 2002; Simpson, Jackson et al. 2004; Clemmons 2012). In 
clinical studies, treatment over a longer period with rhIGF-I for individuals with type 1 
diabetes have improved metabolic control (Cheetham, Holly et al. 1995; Acerini, Patton et al. 
1997; Quattrin, Thrailkill et al. 1997; Quattrin, Thrailkill et al. 2001). These results suggest 
that the improved metabolic control seen in paper I might be related to the observed increase 
in IGF-I. A nightly injection of rhIGF-I versus saline was found to increase glucose 
requirements during an overnight euglycemic clamp in young adult type 1 diabetes subjects 
(Acerini, Harris et al. 1998). At the same time, a significant suppression of overnight GH 
secretion was seen, but only for the higher dose of rhIGF-I. Therefore some of the effects of 
rhIGF-I on glucose metabolism may be related to suppression of GH and not directly to 
increased levels of IGF-I. In fact, suppression of GH is often considered the more important 
mechanism. However, O´Conell et al. showed, in a study with a GHR antagonist given to 
acromegaly patients, that IGF-I can increase insulin sensitivity independently of GH secretion 
(O'Connell and Clemmons 2002). Despite the increase of IGF-I in paper I, we did not show 
decreased levels of GH. Although not directly tested, we speculated that lipolysis and 
gluconeogenesis were unchanged, because of the unchanged GH levels. This is in line with 
Simpson et al.’s findings in a clamp study where rhIGF-I had no direct effect on lipolysis 
(Simpson, Jackson et al. 2004). 
In this thesis we used IGFBP-1 to assess hepatic insulin actions (Kotronen, Lewitt et al. 
2008). In paper I we reported decreased overnight IGFBP-1, 6 weeks after changing from 
NPH to glargine in 12 pubertal subjects with type 1 diabetes. However we did not find 
decreased IGFBP-1 20 hours mean, indicating that it was the nightly values of IGFBP-1 that 
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were mostly reduced. Similarly in paper IV we demonstrated that pubertal subjects treated 
from diagnosis of type 1 diabetes with long-acting insulin analogs, glargine or detemir had 
lower 12-month fasting IGFBP-1. These findings demonstrate that long-acting insulin 
analogs provide increased inhibitory action on hepatic IGFBP-1 production and may also 
indicate that inhibitory actions on hepatic glucose output are increased. Our findings are in 
line with earlier studies in adults (Slawik, Schories et al. 2006) and adolescents with type 1 
diabetes (Yagasaki, Kobayashi et al. 2010; Ekström, Skogsberg et al. 2013). 
The increase in IGFBP-1, reported in paper IV, was only seen in the pubertal subjects treated 
with long-acting analogs, and in paper I only pubertal individuals were in the study group. 
Increased hepatic insulin action may be particularly important in puberty when increased GH 
levels, as shown in paper I, induce hepatic as well as peripheral insulin resistance. IGFBP-1 
binds to IGF-I and thereby down-regulates circulating IGF-I activity (Bereket, Lang et al. 
1999). In adolescents IGF-I is relatively lower compared to prepubertal children, a finding 
that may be due to increased insulin resistance (Zachrisson, Dahlquist et al. 2000). The 
suppression of IGFBP-1 by long-acting insulin analogs, seen in both papers I and IV, 
indicates that hepatic insulin action/sensitivity is increased, which could also impact on the 
production of IGF-I (Shishko, Dreval et al. 1994).  
IGFBP-1 is directly regulated by insulin and therefore displays a diurnal variation with peak 
levels fasting in the morning. This may therefore contribute to the glucose rise in dawn by 
decreasing the bioavailability of IGF-I (Cotterill, Daly et al. 1995; Kobayashi, Amemiya et al. 
1997). In paper IV samples for IGFBP-1 determinations were obtained at diagnosis at random 
times and in the non-fasting state. Despite the non-fasting conditions, it was largely elevated 
and then quickly decreased following iv.insulin administration. Bereket et al. reported 
relatively higher IGFBP-1 levels at diagnosis, but they obtained fasting samples from their 
newly diagnosed patients (Bereket, Lang et al. 1995). They did not report the effect of 
iv.insulin, which we found to be very efficient in suppressing IGFBP-1. Although the long-
acting insulin analogs enhanced the inhibition of IGFBP-1 in the pubertal children, IGFBP-1, 
fasting samples remained high throughout the 12 months. This is surprising, since most 
subjects had the capacity to secrete endogenous insulin in response to a MMTT. However, 
the high IGFBP-1 levels in the fasting state suggest that endogenous insulin may be 
suppressed by daily insulin therapy. 
Higher IGFBP-1 levels were observed in the prepubertal versus pubertal children in paper IV. 
This is in accordance with previous observations of healthy subjects (Strasser-Vogel, Blum et 
al. 1995; Juul, Flyvbjerg et al. 1996). It may be a result of higher endogenous insulin 
secretion and/or higher insulin doses per kg in pubertal children with type 1 diabetes. The 
role of endogenous insulin, with direct hepatic action on IGFBP-1 production, is supported 
by our finding of an inverse correlation between C-peptide AUC and IGFBP-1in the 
relatively newly diagnosed children in paper IV. Multivariate analysis demonstrated that 
endogenous insulin production was the main predictor of IGFBP-1 at 6 months when C-
peptide AUC peaked. The loss of correlation at 12 months may suggest an increasing 
dependency of IGFBP-1 inhibition on exogenous insulin. Contrary to our finding of increased 
IGFBP-1 with age, in a study of children and adolescents with type 1 diabetes Strasser-Vogel 
et al. showed an abolished age dependence in IGFBP-1 (Strasser-Vogel, Blum et al. 1995). 
This is in agreement with earlier literature (Batch, Baxter et al. 1991). The reason for us to 
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find an age and puberty dependency of IGFBP-1 is probably due to the finding mentioned 
above, that when studying subjects with type 1 diabetes with a disease duration of 1 year, 
most subjects still have relatively well preserved endogenous insulin production and are 
therefore less dependent on exogenous insulin. Thus IGFBP-1 is more related to age and 
puberty. 
In both papers I and III we showed improved HbA1c with long-acting analogs. In paper IV, 
when comparing 12-month values of HbA1c in paper III, to IGFBP-1 or IGF-I, there were no 
correlations, although several other studies have found such correlations (Brismar, Fernqvist-
Forbes et al. 1994; Strasser-Vogel, Blum et al. 1995).The lower levels of IGFBP-1 seen with 
long-acting analogs in both papers I and IV, might have had an effect on the lower HbA1c, 
by increasing circulating IGF-I bioactivity (Bereket, Lang et al. 1999). Free circulating IGF-I 
has earlier shown to increase, when IGFBP-1 decreases (Shishko, Dreval et al. 1994; Frystyk 
2004). However it is not clear how changes in free circulating IGF-I are related to changes at 
the tissue level. Because of methodological issues we did not measure IGF-I bioactivity in 
serum by KIRA or free IGF-I assays. (Bang, Ahlsen et al. 2001). Our group performed a 
comparison of two different assays for determination of free dissociable IGF-I (fdIGF-I) and 
found that measuring fdIGF-I by IRMA is of physiological relevance and correlates with 
concomitant changes in insulin sensitivity (Bang, Thorell et al. 2015) and this method can be 
used in the future to determine fdIGF-I. Previously our group had also developed a 
microdialysis technique to access tissue IGF-I concentrations (Berg, Gustafsson et al. 2007), 
but this method was not feasible with the large number of subjects studied in paper IV and 
was not used for this purpose in paper I. 
In paper IV we found an inverse correlation between IGF-I SDS and C-peptide AUC at 12 
months. This was not what we expected, given that hepatic insulin is important for IGF-I 
production (Daughaday, Phillips et al. 1976; Maes, Underwood et al. 1986), and IGF-I may 
be involved in the regeneration of the beta cell (Sorensen, Birkebaek et al. 2015). At 12 
months, IGF-I SDS was lost as a predictor of C-peptide in a multivariate analysis, where age 
and pubertal stage predicted C-peptide AUC. In contrast to our findings Bizzarri et al. 
reported a positive correlation between IGF-I SDS and fasting C-peptide in adolescents on 
CSII or MIT regimen (Bizzarri, Benevento et al. 2014). They found higher IGF-I SDS in 
pubertal (mean -1.2) than prepubertal (mean -1.6). Also this contrasts our findings in paper 
IV and our previous work (Zachrisson, Brismar et al. 1997; Zachrisson, Dahlquist et al. 
2000), but it is in line with what others have found (Strasser-Vogel, Blum et al. 1995). Taking 
data from papers I and IV together, recently diagnosed pubertal subjects have IGF-SDS 
closer to normal than those with a longer diabetes duration, which suggests that endogenous 
insulin may still have an impact on the levels of IGF-I. 
In paper IV, we did not find any differences in IGF-I SDS or IGFBP-1 between the two long-
acting analogs. Ma et al. investigated the acute effect of a single insulin dose on IGFBP-1 
AUC 6-12 hours after injection in a crossover study (Ma, Christiansen et al. 2014). They 
found more suppression of IGFBP-1 levels with detemir versus NPH or glargine. We believe 
that this finding may depend on the study design and reflect that the AUC was investigated 
during the peak effect of detemir. Furthermore, the long-term effects may be very different 
from acute changes. 
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7 CONCLUSIONS AND FUTURE PERSPECTIVES 
The overall results of this thesis support the hypothesis that long-acting analogs, improves 
short- and long-term metabolic control in type 1 diabetes, by showing improved HbA1c with 
glargine or detemir in pubertal subjects both changing from previous therapy with NPH and 
from diagnosis of disease. The abnormalities in the GH-IGF-axis are partly reversed with 
better suppression of IGFBP-1, a marker of hepatic insulin sensitivity. In patients with 
previous NPH treatment, a short-term effect of glargine was observed with a 50 % increase in 
IGF-I suggesting that patients who have lost endogenous insulin can benefit from treatment 
change to long-acting insulin analogs. The marked increase in IGF-I in these patients did not 
restore normal IGF-I SDS and consequently did not suppress GH hyper secretion. In contrast 
to what we hypothesized, there was no impact of glargine or detemir on C-peptide levels or 
their decline over the first year. 
In conclusion, pubertal subjects with type 1 diabetes benefit from improved nightly insulin 
delivery achieved by long-acting insulin analogs. In order to get the long-term benefits of an 
optimal treatment, this thesis supports that pubertal children with type 1 diabetes should be 
treated from diagnosis with glargine or detemir as the first drug of choice for injection 
therapy. If prepubertal children are started on NPH, the results from this thesis suggest that 
they should be changed to glargine or detemir when approaching puberty. However, the 
scientific support for the latter is weaker as it is not based on an RCT. Normal IGF-I and GH 
levels are likely to be of importance for delaying long-term vascular complications. However, 
it is unlikely that subcutaneous injection therapy as monotherapy could achieve this goal 
given the results from this thesis on long-acting insulin analogs and those from a previous 
thesis from our group, dealing with CSII therapy and the GH-IGF-axis. New approaches will 
be needed to accomplish this. Some potential future options are outlined below. 
 Our studies show that the use of long-acting analogs are beneficial for both improving 
metabolic control and restoring the changes in the GH-IGF-axis. Whether the ultra-
long-acting insulin degludec, which has just been approved for use in children, has 
beneficial effects on the changes in the GH-IGF-axis needs to be further explored in 
clinical studies on children and adolescents. The most important factor for success of 
a new insulin analog may not only be related to challenge of meeting the insulin 
requirements. It may also require a more hepatophilic insulin, a characteristic that has 
been reported to be associated with degludec. 
 
 As mentioned, several studies have demonstrated that treatment with rhIGF-I as an 
adjuvant to intensive insulin therapy reverses the GH-IGF-axis in adolescents with 
type 1 diabetes. When these studies were first conducted a fear was raised by EMA 
for the risk of accelation of already started complications, particularly retinopathy. 
However, it is likely that the development of complications are dependent on IGF-I 
and that the dependency changes in different developmental stages of the disease. 
This is suggested by the unravelling of the role of IGF-I in rethinopathy of the 
premature (ROP) (Hellstrom, Smith et al. 2013). In the early phase of ROP, IGF-I 
deficiency increases the risk of developing the early changes. Later on, the increase in 
IGF-I precipitates the later changes. Clemmons and Maile have shown that IGF-I 
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signalling is involved in diabetic vascular complications via cross-talk with integrin 
receptors activated by high glucose levels (Clemmons, Maile et al. 2011). It is likely 
that the inbalance between local and circulating IGF-I levels may explain the 
difficulties in understanding the role of IGF-I. Possibly, local tissue levels of IGF-I 
determined by microdialysis relative to circulating levels could be helpful in 
establishing the relationships as the complications develop. 
 
 CSII, combined with a real-time glucose sensor in a closed loop system with 
automated data transfer using control algorithms to automatically regulate insulin 
infusion, the so called “artifical pancreas”, has been tested in clinical out patient 
settings in adults (Kovatchev, Renard et al. 2014) and in children overnight (Nimri, 
Muller et al. 2014). A closed loop system with diluted insulin used overnight has also 
been shown to decrease hypoglycemia and glucose variability in young children 
(Elleri, Allen et al. 2014). This may be as close to the physiological insulin profile 
that one can get, although the insulin is delivered subcutaneously and will probably 
not be able to normalize the GH-IGF-axis completely. 
 
 Intraperitoneal insulin delivery provide portal delivery of insulin and has been shown 
to increase, but not completely normalize IGF-I in several studies (Hanaire-Broutin, 
Sallerin-Caute et al. 1996; Hedman, Frystyk et al. 2014). Continuous Intra Peritoneal 
Insulin Infusion (CIPII) is used in clinical practice, either with an implantable pump 
or a subcuteous port system- Diaport®. A long-term follow up, over 7 years, showed 
less hypoglycemias, but no difference in HbA1c with CIPII (van Dijk, Logtenberg et 
al. 2014). CIPII is associated with many complications and with high costs. It is 
therefore a therapeutic approach for only the most severly ill patients with extreme 
insulin resistance or in whom autonomaous neuropathy causes severe hypoglycemic 
unawareness. CIPII has been shown to decrease IGFBP-1 more than with CSII (van 
Dijk, Logtenberg et al. 2014). CIPII combined with glucose sensing in the peritoneal 
space may be more efficient regulating infused insulin levels (Burnett, Huyett et al. 
2014). Even with such improvements, CIPII is going to be a treatment for a very 
limited number of patients. 
 
 Intraportal insulin delivery is shown to fully normalize the changes in IGF-I and 
IGFBP-1. This is only used in research settings, but is the ideal way to deliver insulin. 
  
 Beta cell transplantation can provide portal delivery, if the beta cells are infused into 
the liver and the insulin is secreated into the portal circulation. This results in higher 
IGF-I levels than systemic drainage (Frystyk, Ritzel et al. 2008). Again this is going 
to be a treatment for a limited number of patients. 
 
 In our RCT, the use of long-acting analogs from diagnosis of type 1 diabetes did not 
improve preservation of beta cell capacity during the first year. Several achievements 
using different immunmodulators have failed to markedly improve beta cell rest 
without too serious adverese events. Different combination treatments, with a goal of 
affecting several aspects of beta cell destruction (Ludvigsson 2014), such as a 
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combination of an early intensive insulin treatement with a more optimal 
insulinization and a immunmodulating agent, such as GAD65, and anti inflammatory 
treatment, may hopefully become effective. Despite this research, there is not 
currently an established treatment and even in newly diagnosed patients with high 
endogenous insulin secretion we found low IGF-I levels. 
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